© 2011 Society for Laboratory Automation and Screening www . slas . org 1153 IntroductIon M embers of the silent information regulator family ( sirt or sirtuins ) are evolutionarily conserved naD - dependent protein deacetylases and adenosine diphos - phate ( aDP ) – ribosylases . there are seven known isoforms ( sirt1 – 7 ) that differ in their subcellular localization , substrate specificities , and functions ( table 1 ) . 1 – 3 an initial report indi - cated that sirt1 , 6 , and 7 are predominantly nuclear , sirt2 is cytoplasmic , and sirt3 – 5 are localized in the mitochondria . 4 however , it has subsequently been shown that movement of sirt1 and sirt2 between cytoplasmic and nuclear compart - ments may occur , 5 , 6 perhaps indicative of substrate localization . sirtuins catalyze the deacetylation of lysine residues on histones and various proteins , resulting in a deacetylated product , nicoti - namide , and o - acetyl - aDP - ribose . 7 for at least sirt1 , kinetic analysis indicates that lysine deacetylation activity follows a sequential mechanism , whereby the acetylated substrate and naD ( + ) must both bind prior to initiating catalysis . 8 it should be pointed out that although all seven sirtuins are classified as dea - cetylases ( largely based on structural homology ) , the catalytic activity of sirt4 – 7 has been associated primarily with aDP - ribosylation . indeed , little or no lysine deacetylase activity has been found with purified sirt4 or sirt6 enzymes . 9 , 10 it is pos - sible that the biological functions of these isoforms are more closely related to aDP - ribosylation than with lysine acetylation or recognize a specific lysine - containing motif in a protein sub - strate yet to be determined . additional less well - characterized posttranslational modifications have been associated with sirtuin activity , such as depropionylation , 11 but their biological impact has yet to be demonstrated . sirtuins have garnered a great deal of interest in the short time since their discovery . as such , a treatise on the entire sir - tuin family could fill volumes . the founding member of this class of deacetylases , sirt1 ( homolog of yeast silent informa - tion regulator , sir2 ) , is the most widely studied of the sirtuins . early reports in yeast described sir2 / sirt1 as a promoter of genomic stability and enhancer of viability / lifetime . 12 , 13 sirt1 has consequently been associated with aging processes , neural plasticity , and memory , as well as a variety of human disease conditions such as metabolic syndrome , inflammation , neuro - degeneration , and cancer . 3 , 14 because of these pleiotropic func - tions , sirt1 has gained considerable interest by the pharmaceutical industry as a prospective drug target . however , it is unclear whether an activator inhibitor approach will pro - duce the desired therapeutic outcome in the absence of ( or minimal ) unwanted side effects . a thorough understanding of sirtuin biology is needed to establish physiologically relevant enzymatic and cellular assays to screen for these pharmaco - logical modulators . the complexities of sirt1 biology and screening assays have revealed the potential for artifacts and / or misinterpretation . this review is devoted to summarizing the 1 singapore institute for Clinical sciences , agency for science , technology and research ( a * star ) , singapore . 2 lilly research laboratories , eli lilly & Company , indianapolis , indiana . received Jun 17 , 2011 , and in revised form Jul 26 , 2011 . accepted for publica - tion aug 8 , 2011 . Journal of biomolecular screening 16 ( 10 ) ; 2011 Doi : 10 . 1177 / 1087057111422103 Sirtuin 1 ( SIrt1 ) : the Misunderstood HdAc WALter StünkeL 1 and robert M . cAMpbeLL 2 the sirtuin family of naD - dependent histone deacetylases ( hDaCs ) consists of seven mammalian proteins , sirt1 – 7 . many of the sirtuin isoforms also deacetylate nonhistone substrates , such as p53 ( sirt1 ) and α - tubulin ( sirt2 ) . the sirtuin litera - ture focuses on pharmacological activators of sirt1 ( e . g . , resveratrol , srt1720 ) , proposed as therapeutics for diabetes , neurodegeneration , inflammation , and others . however , many of the sirt1 activator results may have been due to artifacts in the assay methodology ( i . e . , use of fluorescently tagged substrates ) . a biological role for sirt1 in cancer has been given less scrutiny but is no less equivocal . although proposed initially as an oncogene , we present herein compelling data sug - gesting that sirt1 is indeed a context - specific tumor suppressor . for oncology , sirt1 inhibitors ( dual sirt1 / 2 ) are indi - cated as potential therapeutics . a number of sirtuin inhibitors have been developed but with mixed results in cellular systems and animal models . it is unclear whether this has been due to poorly understood model systems , signalling redundancy , and / or inadequately potent and selective tool compounds . this review provides an overview of recent developments in the field of sirt1 function . While focusing on oncology , it aims to shed light on new concepts of expanding the selectivity spectrum , including other sirtuins such as sirt2 . ( Journal of Biomolecular Screening 2011 : 1153 - 1169 ) key words : epigenetics , metabolic diseases , cancer and cancer drugs , immune system diseases , Cns and Pns diseases Stünkel and campbell 1154 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 table 1 . the sirtuin family of Protein Deacetylases / aDP - ribosyltransferases : Known Crystal structures , subcellular localization , substrates , and Phenotypes from Knockout / Deficient mice SIRT Isoform Crystal Structure Localization Substrates Knockout Mouse Phenotype sirt1 human ( none ) , yeast ( hst2 ) , 169 - 171 Escherichia coli ( cobb ) , 172 Thermotoga maritima ( sir2 - tm ) , 173 - 175 Archaeoglobus fulgidus ( sir2 - af1 / 2 ) 176 - 178 nucleus ( can shuttle to cytoplasm ) h3K9 , h4K16 , 15 , 16 p53 , 24 , 25 p73 , 26 foX01 , foX03a , foX04 , 27 - 30 Pten , 31 niCD , 32 mef2 , 33 hif - 1α , hif - 2α , 34 - 36 taf ( i ) 68 , 37 srebP - 1c , 38 β - catenin , 39 rela / p65 , 40 , 41 PgC1α , 42 bmal1 , Per2 , 43 , 44 Ku70 , 45 XPa , 46 smaD7 , 47 cortactin , 48 irs - 2 , 49 , 50 aPe1 , 52 PCaf , 53 tiP60 , 54 p300 , 20 , 28 , 55 , 56 suV39h1 , 57 aceCs1 , 58 , 59 PParγ , 60 erα , 61 ar , 62 lXr 63 reduced life span , tumor suppressor , or oncogene depending on mouse genetic background , genomic instability , developmental defects , autoimmune syndrome 17 , 23 , 39 , 100 - 102 , 117 , 119 , 179 sirt2 human 180 Cytoplasm ( can shuttle to nucleus ) h4K16 , 181 h3K56 , 20 α - tubulin 182 none reported sirt3 human 183 mitochondria ( can shuttle to nucleus ) h4K16 , 184 h3K56 , 20 Ku70 , 185 iDh2 , 186 , 187 hmgCs2 , 188 gDh , 187 aceCs , 58 , 189 sdha , 190 soD2 , 191 , 192 lCaD 193 normal , increased reactive oxygen species ( ros ) levels , decreased adenosine triphosphate ( atP ) levels 194 , 195 sirt4 none reported mitochondria glutamate dehydrogenase ( gDh ) ( aDP - ribosylation ) 196 normal , gDh activation 197 sirt5 human 198 mitochondria Cytochrome C , 187 CPs1 199 urea cycle dysfunction , hyperammonemia following fasting 199 sirt6 human 10 nucleus h3K9 , 200 , 201 h3K56 202 lethal around 4 weeks , lymphopenia , decreased subcutaneous fat , bone loss , decreased igf1 , metabolic defects 203 sirt7 none reported nucleus ( nucleolus ) rna Pol i ( ? ) , 204 p53 159 reduced life span , kyphosis , decreased subcutaneous fat , degenerative cardiac hypertrophy 159 no deacetylation activity has been found with sirt4 thus far . it is unclear whether rna polymerase i is a direct target of sirt7 . 204 although deacetylation activity has been reported for sirt6 , other reports suggest it is primarily an aDP ribosyltransferase . 10 biochemical / biological activities of sirt1 , status of chemical modulators ( activators , inhibitors ) , assay considerations , and suggestions for paths forward in sirtuin drug discovery . SIRT1 substrates—histones Yeast and mammalian sir2 / sirt1 will deacetylate a vari - ety of histones at specific lysine residues : h1 ( K26 ) , h3 ( K9 , K14 ) , and h4 ( K16 ) in vitro . 15 , 16 of these mark changes observed biochemically , elevation in h3K9 and h4K16 acety - lation is seen in sirt – / – mef cells . 17 loss of h4K16 acetyla - tion and h4K20 trimethylation are commonly observed in human cancers . 18 in yeast , there is an age - associated increase in h4K16 acetylation and concomitant decrease in sir2 ( sirt1 ) protein , causing reduced transcriptional silencing . 19 these early observations were key drivers of investigations into the role of sirt1 in cancer and aging . recently , sirt1 was found to suppress p300 - mediated h3K56 acetylation 20 , 21 at the bclaf1 promoter , thereby reducing t cell activation . 21 sirt1 knockout mice develop an autoimmune syndrome , with increased t cell activation and disruption of CD4 + t cell tol - erance . 22 , 23 given this evidence , sirt1 , perhaps via h3K56 deacetylation , may play a role in innate and adaptive immune function . SIRT1 substrates—nonhistones sirt1 can deacetylate a number of nonhistone substrates , suggesting a broader role than just epigenetic silencing . one of Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1155 the first substrates of sirt1 identified was p53 ( p53K382 ) , a well - known tumor suppressor , which resulted in repression of p53 - dependent apoptosis in response to Dna damage and oxi - dative stress . 24 , 25 sirt1 deacetylates quite a number of other nonhistone proteins , including other tumor suppressors , tran - scription factors , signaling proteins , enzymes , and nuclear hor - mone receptors : p73 ( putative tumor suppressor involved in cell cycle and apoptosis ) 26 ; foX01 , foX03a , and foX04 ( forkhead transcription factors ) 27 – 30 ; Pten ( tumor suppressor regulating Pi3K / aKt pathway ) 31 ; niCD ( notch1 intracellular domain ) 32 ; myocyte enhancer factor , mef2 ( transcription factor ) 33 ; hypoxia - inducible factors hif - 1α , - 2α 34 – 36 ; taf ( i ) 68 ( Pol i transcription ) 37 ; srebP - 1c ( transcription factor modulating hepatic lipogenesis ) 38 ; β - catenin ( component of Wnt signaling pathway ) 39 ; rela / p65 ( nfκb signaling ; immune function ) 40 , 41 ; PgC1α ( nuclear coactivator involved in control of gluconeo - genic genes ) 42 ; bmal1 and Per2 ( circadian rhythm / clock pro - teins ) 43 , 44 ; Ku70 ( Dna repair protein ) 45 ; XPa ( nucleotide excision repair ) 46 ; smaD7 ( tgfβ - induced signaling protein ) 47 ; cortactin ( promotes cell migration ) 48 ; irs - 2 ( neuroprotec - tion ) 49 , 50 ; tau ( neurodegeneration ) 51 ; aPe1 ( apurinic / apyrimi - dinic endonuclease - 1 , base - excision repair pathway ) 52 ; PCaf 53 ; tiP60 54 ; p300 histone acetyltransferases ( inflammation , Dna damage response ) 20 , 28 , 55 , 56 ; suV39h1 ( histone methyltrans - ferase ) 57 ; aceCs1 ( acetyl Coa synthetase ) 58 , 59 ; and PParγ , 60 erα , 61 ar , 62 and lXr 63 nuclear hormone receptors . given the multitude of potential substrates and the lack of a defined consensus sequence , 64 it is possible that sirt1 sub - strate selectivity may be defined by cellular localization in the presence of sirt1 chaperones / partners in a given complex . sirt1 has been reported to shuttle between the cytoplasm and the nucleus upon various stimuli and has “compartment - dependent” functions . 6 , 65 , 66 SIrt1 And MetAboLIc FunctIonS sirt1 can be considered a master regulator of cellular metabolic pathways . 67 sirt1 plays a direct role in transcrip - tional silencing and , via direct interaction with specific co - repressors , exerts profound effects on metabolic pathways such as lipogenesis and gluconeogenesis . Data suggest that sirt1 is involved in the central regulation of food intake 68 and regula - tion of the circadian clock . 69 its major function in metabolism may be to act as a “nutrient sensor . ” sirt1 has been shown to affect lipogenesis through the regulation of mitochondrial acetyl - Coa synthetase 58 and PParγ . 70 interestingly enough , PParγ directly interacts with sirt1 and inhibits sirt1 activ - ity , forming a highly regulated negative feedback loop . 60 sirt1 has also been implicated in control of metabolic glucose . the deacetylation of lXr by sirt1 suggests a role in cholesterol and lipid homeostasis . 63 sirt1 promotes gluconeogenic gene induction and fatty acid oxidation at least in part via PgC1α . 71 , 72 sirt1 overexpression in the liver attenuates insulin resist - ance . 73 similarly , sirt1 has been downregulated in insulin - resistant C2C12 cells and muscle tissues , and sirt1 knockdown has produced insulin resistance . 74 this effect was thought to be mediated by PtP1b silencing at the chromatin level . insulin secretion may also be regulated by sirt1 repression of uCP2 in pancreatic cells . 75 subsequently , there have been a multitude of reports linking sirt1 activation to enhanced fatty acid oxi - dation , gluconeogenesis , insulin secretion , insulin sensitivity , and decreased lipogenesis ( reviewed in haigis and guarente 76 and liang et al . 77 ) . therefore , it is not surprising to find great excitement surrounding the development of sirt1 activators for metabolic diseases . SIrt1 And neurodegenerAtIon sirt1 has been postulated to serve a neuroprotective func - tion , suggesting that sirt1 activators may be effective thera - peutics for treating neurodegeneration diseases such as alzheimer disease . alzheimer disease is characterized by dep - osition of β - amyloid ( or amyloid β , aβ ) plaques and tau pro - tein – containing tangles . it is believed that these proteins may be causative in the neuronal and functional loss , which eventu - ally results in death . tau protein is deacetylated by sirt1 , albeit with a modest effect in vitro . 51 tau acetylation prevents degradation of phosphorylated tau ( p - tau ) , so deacetylation ( by sirt1 ) may be neuroprotective . there is compelling evidence linking sirt1 to aβ - peptide production . for example , in mixed cortical cultures , sirt1 overexpression inhibits aβ - induced nfκb activation and cytotoxicity , presumably via the deacetylation of rela / p65 ( K310 ) . 40 , 78 neuronal cells from sirt1 transgenic mice display higher α - secretase activity and attenuated aβ peptide ( 1 – 40 and 1 – 42 ) production . 79 introducing a sirt1 transgene to a mouse model of alzheimer disease ( aPPswe / Psen1de9 ) similarly causes an activation of α - secretase and subsequent reduction in alzheimer disease – related aβ peptides . 80 Conversely , reduction of sirt1 via expression of a dominant negative sirt1 construct augments the accumulation of aβ peptides by neuronal cells in vitro . 81 it is conceivable that sirt1 activators may attenuate aβ peptide and tau production and thereby have utility in alzheimer dis - ease therapy . indeed , sirt1 lentiviral insertion in the hip - pocampus was neuroprotective in an inducible p25 transgenic mouse model of alzheimer disease . 82 as mentioned , the activity of sirt1 may be regulated by its nuclear / cytoplasmic localization . upon exposure to neuronal cell precursor differentiation conditions , sirt1 quickly trans - locates from the cytoplasm to the nucleus and later moves back to the cytoplasm . 65 overexpression of sirt1 in these cells promoted differentiation , but this was not seen with a cytoplas - mically restricted sirt1 mutant . 65 similarly , cytoplasmic sirt1 ( but not nuclear ) increased ngf - induced neurite Stünkel and campbell 1156 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 outgrowth of PC12 cells . 66 both studies suggest that sirt1 localization was critical to activity . SIrt1 And tHe IMMune SySteM sirt1 is a potent negative regulator of nfκb transcription , at least in part due to direct rela / p65 deacetylation . 40 Data from both overexpression and knockout / down models are con - sistent with an anti - inflammatory role for sirt1 . in mouse macrophages overexpressing sirt1 , nfκb activity is decreased relative to Wt , whereas this effect is not seen with knock - in of a catalytically inactive sirt1 [ h355a ] mutant . 83 mice with myeloid - specific sirt1 knockout display hypera - cetylated nfκb , resulting in elevated transcriptional activation of proinflammatory macrophage target genes . 41 smokers and patients with chronic obstructive pulmonary disease ( CoPD ) have decreased lung sirt1 levels ( especially in alveolar mac - rophages , airway epithelium , and alveolar epithelium ) . 84 Cigarette smoke reduces sirt1 levels in a human monocyte - macrophage cell line ( monomac6 ) , leading to acetylation of the rela / p65 subunit of nfκb and elevation in levels of inter - leukin ( il ) – 8 . it was postulated that reduction of sirt1 and resulting nfκb hyperactivation could possibly be the basis of the chronic inflammatory response , such as in CoPD . 84 in pri - mary mouse peritoneal macrophages , sirt1 suppresses aP - 1 transcriptional activity and CoX - 2 expression . 85 it was also found that raW264 . 7 macrophage - like cells transfected with sirt1 demonstrated improved phagocytic function . in the neonatal cardiomyocyte , sirt1 may depress the inflammatory response , as adenoviral overexpression of sirt1 in these cells blocked phenylephrine - stimulated mCP1 mrna ( monocyte chemoattractant protein – 1 ) and acetylation of rela / p65 and PgC1α . 86 sirt1 may modulate nfκb as a pivotal point in the regulation of endotoxin tolerance , shepherding the transition from an inflammatory to an adaptive state . following lPs stimulation of thP - 1 monocytic cells or infusion in vivo , sirt1 protein transiently decreases ( 8 – 12 h ) and later returns to 87 or exceeds baseline . 88 sirt1 binds to the promoters of tumor necrosis factor α ( tnfα ) and il - 1β in the thP1 cell , deacetylates rela / p65 ( presumably when in complex at the promoter ) , and represses transcription of these proinflamma - tory cytokines . 88 it is believed that , over time , expression of namPt ( nicotinamide phosphoribosyltransferase , a key enzyme in naD biosynthesis ) and thus naD + is increased , stimulating relb expression and recruitment to sites of tran - scription . this “feed - forward” loop resulting in sustained epi - genetic silencing may be the mechanism that produces endotoxin tolerance . 88 as mentioned previously , sirt1 - null mice display autoim - mune - like symptoms , such as the accumulation of immune com - plexes in liver and kidney , as well as the presence of antinuclear antibodies . 23 it is thought that hiV - 1 may act to interfere with sirt1 function and decrease immune surveillance . hiV - 1 tat protein binds to the deacetylase domain of sirt1 and inhibits sirt1 - mediated deacetylation of rela / p65 . 55 , 89 Consequently , nfκb transactivation is greatly potentiated , causing t cell hyperactivation , increased viral replication , and eventually the depletion of CD4 + t cells . targeted deletion of sirt1 in specific t cell populations reveals a contrasting view to global knockout ( i . e . , where data suggest that sirt1 dampens the inflammatory response and suppresses immune response ) . however , when sirt1 was deleted specifically in CD4 + t cells and foxp3 + treg cells , activation , proliferation , and cytokine production were unal - tered relative to wild type . 90 also seen was an increase in foxp3 expression , a protein associated with an immunosup - pressive phenotype , and enhancement of allograft survival . as these results were recapitulated by sirt1 inhibitors , eX527 and splitomicin , 90 one could certainly make a case for the use of sirt1 inhibitors in preventing allograft rejection . dIcHotoMIc FunctIonS oF SIrt1 In cAncer studies of sirt1 function in cancer are littered with seem - ingly contradictory data , with some suggesting sirt1 is a tumor suppressor and others indicating that sirt1 may be tumorigenic . expression data are equivocal , as sirt1 is over - expressed in certain tumors ( prostate , hepatocellular carci - noma , breast ovarian epithelial , gastric carcinoma , colorectal , melanoma ) 91 – 98 while reduced in several others ( bladder , colon carcinoma , glioblastoma , ovary , and prostate ) . 17 , 99 in vivo , the presence or absence of other mutations in key tumor survival pathways may serve to determine the fate of sirt1 function . another thought to consider is that sirt1 may normally pro - tect the cell from oncogenic transformation , but upon or after transformation , sirt1 signaling is co - opted to promote malig - nant growth ( i . e . , those pathways that serve to protect normal cells may prevent the death of cancer cells ) . the various lines of evidence are presented herein with the suggestion that sirt1 function is context dependent . SIRT1 as a tumor suppressor sirt1 knockout and transgenic mouse studies led to the speculation that under certain circumstances , sirt1 may act as a tumor suppressor . 100 in the presence of aPC min / + mutation , sirt1 overexpression reduced polyp formation in mice , a potential precursor to colorectal cancer . 39 however , when using aPC min / + , sirt – / – mice , the presence of intestinal polyps was unchanged relative to aPC min / + , sirt + / + counterparts ( i . e . , the absence of sirt1 did not yield a greater number of polyps ) . 101 additional studies support the concept of sirt1 as a tumor suppressor . for example , sirt1 + / – , p53 + / – mice develop tumors Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1157 in multiple organs . 17 in another model , homozygous deletion of sirt1 in mice led to the development of prostatic intraepithe - lial neoplasia , which was thought to be mechanistically linked with decreased autophagy . 102 in contrast , skin papilloma devel - opment was unchanged by sirt status ( sirt1 – / – or sirt1 + / – mice ) in a model of chemically induced skin carcinogenesis . 101 nucleotide excision repair ( ner ) is conducted by the care - ful orchestration of many proteins , including aPe1 , nbs1 , XPa , and XPC , to remove and , where possible , fix damaged Dna . apurinic / apyrimidinic endonuclease - 1 , aPe1 , is essen - tial for the repair of single - strand Dna lesions . nijmegen breakage syndrome protein , nbs1 , is part of the larger mre11 - raD50 - nbs1 nuclease complex involved in the detection and repair of damaged Dna . XPa and XPC ( xeroderma pigmento - sum proteins a or C ) are also responsible for sensing the Dna breaks and recruiting repair proteins to the site of damage . it was recently reported that sirt1 could deacetylate and acti - vate each of these proteins ( aPe1 , nbs1 , XPa , XPC ) directly , enhancing ner and cell survival . 46 , 52 , 103 , 104 sirt1 knockdown causes cells to become more sensitive to killing by a variety of genotoxic stresses—for example , uV , h2o2 , and mms ( aba - sic Dna damaging agent ) —potentially due to hyperacetylation of these ner factors . sirt1 – / – mefs and keratinocytes with sirt1 knockdown show dramatically reduced XPC levels , increased aKt ser473 phosphorylation , and a diminished ability to excise base lesions ( cyclobutane pyrimidine dimers ) caused by uV irradiation . 103 the effect on aKt phosphorylation is consistent with previous data showing that sirt1 deacetylates Pten , counteracting acetylation - induced repression of its phosphatase activity , thereby activating aKt . 31 given the well - known oncogenic role of aKt , these data would strongly suggest a tumor - sup - pressing role for sirt1 under these conditions . Downstream of aKt , sirt1 has been shown to interact with tsC2 , a member of the mammalian target of rapamycin complex . 105 sirt1 negatively regulates mtor signaling , implying that targeting sirt1 would enhance mtor activity , which is contraindi - cated in cancer therapy . to complicate the situation further , sirt1 is phosphorylated ( ser47 ) by mtor , resulting in the inhibition of sirt1 catalytic activity . 106 more recently , it was shown that the aKt / mtor pathway is activated in brCa1 - mutated cancers mediating tumorigenesis . 107 brCa1 mutant - dependent breast cancers were found to have decreased sirt1 and increased survivin expression compared to controls . 108 overexpression of sirt1 hindered brCa1 - dependent cancer formation in vitro . survivin and other parts of the Wnt signaling pathway have been shown to foster the proliferative state of stem cells . 109 sirt1 was reported to deacetylate β - catenin , leading to inhibition of proliferation of colon cancer cells . 39 the non - oncogenic cytosolic form of β - catenin was found to be enhanced by sirt1 , coinciding with co - localization of nuclear sirt1 and the oncogenic form of β - catenin in a cohort of 81 human colon tumors . 39 however , in another study , sirt1 shrna caused a reduction in Dishevelled proteins DVl - 2 and DVl - 3 in t47D and heK - 293 cells , suggesting multiple regulation points in the Wnt signaling by sirt1 . 110 stem cell function highly depends on the transcription factor environment . for example , c - myc is part of a transcription factor network that can reverse the differentiated phenotype back to pluripotent and proliferative stem cells ( reviewed in Papp and Plath 111 ) . in the same way described for the p53 - hiC1 - sirt1 axis and its function on the sirt1 promoter , the oncogenic transcription factor c - myc constitutes a negative feedback loop with sirt1 leading to downregulation of c - myc activity , another potential antitumor effect . 112 in light of the putative stem cell function of c - myc , sirt1 - mediated c - myc downregulation in cancer stem cells may lead to differentiation , a trait highly aligned with a potent tumor suppressor function . SIRT1 as tumor promoter / oncogene there is evidence that sirt1 may play an oncogenic role by inactivation of tumor suppressors and / or activation of onco - genic proteins . hiC1 ( hypermethylated in cancer 1 ) is a tumor suppressor that can be either epigenetically silenced or deleted in various cancers . 113 , 114 hiC1 constitutes a circular regulatory feedback loop with p53 and sirt1 , such that inactivation / absence of hiC1 derepresses sirt1 , triggering sirt1 activa - tion and p53 inactivation via deacetylation . 115 , 116 hic1 + / – , apc + / Δ716 double - heterozygous mice have increased numbers of intestinal polyps , leading to hyperplasia . 117 if indeed the hiC1 - sirt1 - p53 loop were in effect , this would provide indirect evidence for sirt1 as a tumor promoter ( i . e . , in the context of hiC1 and aPC ) . sirt1 may also promote oncogenesis via the stabilization of n - myc . n - myc induces sirt1 transcription in neuroblastoma , which then enhances n - myc stability in a positive feedback loop . 118 this is thought to be accomplished by sirt1 - induced repression of mKP3 phosphatase , leading to increased erK phosphorylation ( i . e . , decreased de - phosphoryl - ation ) and then n - myc ser62 phosphorylation , which protects n - myc from degradation . 118 these observations are seemingly contradictory to the tumor suppressor activities of sirt1 men - tioned previously . one could speculate that specific genetic disruptions ( i . e . , such as seen with hic1 ) effect a molecular switch , turning sirt1 from a tumor suppressor to an oncogene . for n - myc , the specific mutation effecting this switch has yet to be elucidated . some of the most intriguing animal data for sirt1 as an oncogene come from the recent 2011 american association for Cancer research ( aaCr ) meeting , where serrano 119 reported that sirt1 transgenic crossed with Pten - null mice produced aggressive thyroid and prostate carcinomas . these thyroid tumors were enriched in cmyc and cmyc targets ( but not p53 , Stünkel and campbell 1158 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 p65 , or β - catenin ) and displayed elevated p - aKt levels . more studies will be required to understand the interaction of the Pi3k / mtor pathway , sirt1 , and myc . however , this is the first evidence clearly demonstrating an oncogenic role for sirt1 in vivo . an alternative oncogenic hypothesis is that cancer cells develop addictive mechanisms by which sirt1 overexpres - sion is coupled with aberrant silencing of tumor suppres - sors . 120 addition of transforming growth factor β ( tgfβ ) , known to stimulate epithelial - to - mesenchymal transition ( emt ) , to immortalized human mammary epithelial cells ( htert - hmes ) produces a profound elevation in sirt1 and n - cadherin , as well as a substantial reduction in e - cadherin via direct epigenetic silencing . 121 e - cadherin levels were restored by sirt1 depletion in vitro . anchorage - independent growth and migration of htert - hme cells are inhibited by either sirt1 shrna or mir - 200a . sirt1 and mir - 200a dis - play an inverse relationship , as sirt1 is overexpressed whereas mir - 200a is depressed in breast cancer biopsies . 121 these authors suggest that mir - 200a functions as a tumor suppressor in breast cancer and that reduction in mir - 200a removes the repression of sirt1 , producing sirt1 overex - pression , thus supporting induction of emt . other ways sirt1 could influence tumor suppressor function is via the interaction with other oncogenes such as ski . ski interacts with sirt1 , increasing the binding of p53 to sirt1 and sta - bilizing the p53 - sirt1 interaction . Deacetylation of p53 ( by sirt1 ) is enhanced , which suppresses p53 - dependent tran - scriptional activation . 122 as ski facilitates the p53 - sirt1 interaction , the authors speculated that ski may convey sirt1 substrate selectivity . given the multiplicity of activities attrib - uted to sirt1 and subcellular localization , it seems quite plausible that adapter proteins might exist to associate sirt1 with specific substrates and effector functions . this role for sirt1 , however , is only relevant in those tumors that have intact / competent p53 . sirt1 silencing is reported to cause apoptosis of many tumor lines ( colorectal , breast , cervical ) but not noncancerous lines ( epithelial origin : arPe - 19 , htb - 125 ; and normal fibro - blasts [ nDf ] ) via a p53 - , bcl - 2 - and bax - independent mecha - nism . 123 in the hCt116 colorectal tumor line , co - silencing of foxo4 and sirt1 , but not foxo3 , rescues the cells from apoptosis 123 ( i . e . , suggesting foXo4 is required for the proap - optotic effect in the absence of sirt1 ) . it is quite possible then that the differential sensitivity to sirt1 sirna ( cancer vs . normal ) has a genetic basis , but the enabling molecular target ( s ) are as yet undetermined . in pancreatic cancer , sirt1 levels are inversely correlated with patient survival . sirt1 knockdown in pancreatic tumor lines induces g1 growth arrest and apopto - sis ( miaPaCa , PanC1 ) . 124 sirt1 interference also decreases viability and clonogenic survival of human melanoma tumor lines ( a375 , hs294t , g361 ) 97 and inhibits proliferation of breast ( mCf7 ) and nsClC ( h1299 , p53 - deficient ) cells . 125 , 126 it should be noted that knockdown of both sirt1 and sirt2 was required to induce cell cycle arrest and kill mCf - 7 cells in vitro , 125 suggesting that dual sirt1 / 2 inhibitors might be required for maximal efficacy in breast cancer . sirt1 has been linked to mechanisms of Dna repair , puta - tively serving to protect normal cells against potential carcino - genic agents and / or environmental stresses . another possibility is that during malignant growth , sirt1 provides an antiapop - totic stimulus to maintain the aberrant growth and lifetime of the transformed cells . o’hagan et al . 127 have postulated that chronic exposure to inflammation and / or carcinogens incurring Dna damage could initiate epigenetic silencing of tumor sup - pressor genes . using their exogenous gene promoter model ( containing the Cpg island segment of e - cadherin ) , these investigators found that both sirt1 and eZh2 were transiently recruited to the Dna break site , as well as Dnmt1 and Dnmt3b . Dna methylation and engagement of Dnmt3b were dependent on sirt1 . 127 albeit infrequent in occurrence , gene silencing and Dna methylation were observed in the Cpg island region . these authors provide a compelling argu - ment for sirt1 involvement in aberrant Cpg island Dna methylation and gene silencing contributing to the initiation and / or maintenance of cancer . this may explain why sirt1 and eZh2 proteins are more abundant in cancerous ( Nkx3 . 1 – / – ; Pten – / – mouse model ) versus normal prostate tissue 128 and per - haps also the association of sirt1 overexpression with CimP - high ( Cpg island methylator phenotype ) and microsatellite instability in colorectal cancer . 96 upon Dna damage , the cell triggers a number of key proteins that begin the process of Dna repair and maintain genomic integ - rity , including Ku70 , tiP60 , and e2f1 . Ku70 , a protein that binds to the ends of Dna double - strand breaks and initiates nonhomolo - gous end - joining , is deacetylated by sirt1 . 45 in a model system of radiation - induced Dna damage ( luciferase reporter gene ) , sirt1 expression enhanced annealing of Dna breaks in vitro ; this was not seen using dominant - negative , catalytically inactive sirt1 cells . 45 as such , sirt1 could be acting to enhance Dna repair and cell survival by deacetylation of Ku70 . tiP60 , tat - interacting protein 60 kD , is a histone acetyltransferase required for double - stranded Dna break ( DsDb ) repair following radia - tion . 129 , 130 tiP60 and the mre11 - raD50 - nbs1 ( mrn ) complex act cooperatively to activate atm kinase following Dna damage . mrn is thought to direct atm and tiP60 to the site of DsDbs , where tiP60 and atm become activated . 129 h2aX is then phos - phorylated by atm ( ser139 ) and acetylated ( lys5 ) by tiP60 , 54 , 131 causing cell cycle arrest and apoptosis . tiP60 also acetylates p53 ( K120 ) , enhancing the binding of p53 to proapoptotic genes . 54 sirt1 acts as a negative regulator of tiP60 , directly deacetylating tiP60 , inhibiting tiP60 activation , and promoting tiP60 degrada - tion . 54 , 131 as such , one could envision sirt1 acting to dampen the apoptotic response and promote tumor survival . Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1159 a common recurring theme in sirt1 and cancer is that of promoting cellular resistance toward damaging conditions . sirt1 has been associated with drug resistance 120 or oxidative stress . 25 , 27 , 29 the interaction between e2f1 ( i . e . , a “proapop - totic” factor induced by Dna damage ) and sirt1 perhaps illustrates the conditional nature of sirt1 activity . sirt1 is elevated following etoposide - induced Dna damage , and this is thought to be mediated by e2f1 ( stabilized by atm phospho - rylation ) . 132 e2f1 is also deacetylated by sirt1 and may even recruit sirt1 to its own promoter . this suggests that a feed - back loop between sirt1 and e2f1 may exist to finely control the Dna damage response . in u2os cells co - transfected with sirt1 and e2f , sirt1 was found to inhibit the apoptotic activity of e2f1 . 132 this effect was also seen with hCt116 p53 – / – cells indicating a p53 - independent mechanism . in h1299 non – small cell lung carcinoma , sirt1 knockdown or addition of a nonselective sirt inhibitor , nicotinamide , sensitized cells to etoposide - induced apoptosis . 132 sirt1 may also function to cultivate a microenvironment conducive to tumor growth and metastasis . sirt1 is highly expressed in the nuclei of vascular endothelium . 133 rna silencing of sirt1 , but not sirt - 2 , - 3 , or - 5 , abolishes endothelial cell migration and sprout formation in vitro . the deacetylase activity of sirt1 is required for these activities as a dominant negative mutant [ h363Y ] mimics the effects of sirt1 sirna . 133 as one might expect from the in vitro obser - vations , knockout of sirt1 in mice ( endothelial cell specific : Tie2Cre tg ; SIRT1 flox / – ) or zebrafish ( antisense ) produced a blunted angiogenic phenotype . subsequent data from this laboratory revealed that sirt1 , via deacetylation of nCiD , acts as a negative regulator of notch signaling in endothelial cells . 32 notch is ubiquinated and degraded under deacetylation conditions , so sirt1 could conceivably control the levels of notch . as notch coordinates various aspects of blood vessel growth , the authors speculated that sirt1 may act as “a rheo - stat” to finely tune notch responses in endothelial cells . 32 Cortactin is an f - actin binding protein and src substrate that , in its acetylated form , attenuates cell migration . Cortactin has been shown to potentiate metastasis in breast and esophageal cancer models . 134 , 135 sirt1 deacetylates cortactin and pro - motes cell migration in vitro , 48 suggesting a role for sirt1 in metastasis . pHArMAcoLogIcAL ModuLAtIon oF SIrt1 Enzymatic assays there are now many assay formats to screen sirt1 enzyme for both activators and inhibitors . these include fluores - cence , 136 – 139 time - resolved fluorescence , chemiluminescence , 140 microfluidic mobility shift , 140 fluorescence polarization , 141 mass spectrometry , 141 , 142 capillary electrophoresis , 143 high - per - formance liquid chromatography ( hPlC ) , 7 , 144 and radioac - tive 145 – 147 formats . these are described in more detail within this issue . 142 SIRT1 activators sirt activators are being pursued in hopes of providing benefit to patients with neurodegenerative , inflammatory / autoimmune , and metabolic disease ( perhaps also cancer in certain tumor types ) . however , the most widely published sirt1 activators have caused a great deal of controversy . it is questioned whether many of these compounds are de facto sirt1 activators or assay artifacts . this debate has arisen from a combination of issues associated with enzymatic assay format and compound selectivity . one of the earliest assays used for sirt1 screening , commercialized by biomol ( Plymouth meeting , Pa ) as fluor de lys , 148 contained a flu - orescent - labeled peptide ( p53 - amC ) for a substrate . the first sirt1 activators identified with this assay were poly - phenolic plant - derived compounds : resveratrol , butein , quercetin , piceatannol , and myrcetin ( table 2 ) . 148 , 149 subsequently , much more potent and efficacious sirt1 acti - vators were reported as potential therapeutics for the treat - ment of diabetes ( e . g . , srt1720 , srt2183 , and srt1460 ) , 141 using a fluorescently labeled substrate in a fluorescence polarization assay . it was realized quickly that sirt1 bio - chemical activation by resveratrol could only be demon - strated when the substrate was fluorescently tagged . 150 – 152 using a variety of nonfluorometric assay formats , it was found that all of these four compounds ( resveratrol , srt1720 , srt2183 , and srt1460 ) did not activate sirt1 when using native peptide or protein substrates . 152 , 153 furthermore , srt1720 and srt2183 decreased acetylated p53 levels in sirt1 - deficient ( sirna ) and null ( sirt – / – mefs ) cells , again suggesting sirt1 was not the direct target . one unconfirmed report claimed that srt1720 and srt2183 , but not resveratrol , were actually p300 hat inhibitors , account - ing for their cellular effect on p53 acetylation in the absence of enzymatic modulation . 153 the value of resveratrol , srt1720 , srt2183 , and srt1460 as sirt1 activators becomes even more dubious when taking into account that they inhibit quite a number of nonepigenetic targets ( e . g . , g - protein - coupled receptors [ gPCrs ] , enzymes , and trans - porters ) . 152 the selectivity of piceatannol for sirt1 is also questionable as it inhibits tyrosine kinases such as lck 154 and mitochondrial atP synthase ( as do other polyphenols ) . 155 it is evident that more highly selective sirt1 activators , which show correlative activity in both enzymatic and cellular sirt1 - dependent assays , are still needed to understand sirt1 biology and therapeutic potential . Stünkel and campbell 1160 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 table 2 . small - molecule activators of sirt1 SRT1720 RESVERATROL SRT2183 SRT1460 MYRICETIN BUTEIN QUERCETIN PICEATANNOL C C C OH OH O OH OH O OH OH OH OH O OH OH OH OH OH OH O OH OH OH O OH OH OH OH OH N N O NH N S N N NH O CH 3 O C H 3 O NH N S N N NH O CH 3 O NH N S N N OH SRT1720 RESVERATROL SRT2183 SRT1460 MYRICETIN BUTEIN PICEATANNOL C C C OH OH O OH OH O OH OH OH OH O OH OH OH OH OH OH O OH OH OH O OH OH OH OH OH N N O NH N S N N NH O CH 3 O C H 3 O NH N S N N NH O CH 3 O NH N S N N OH Fold Rate Increase @ 100 µM [ refs . 148 , 149 ] EC 1 . 5 ( % Max ) * [ ref . 142 ] butein 8 . 53 myrcetin 3 . 19 Piceatannol 7 . 90 Quercetin 4 . 59 , 2 . 15 resveratrol 13 . 4 , 4 . 66 46 . 2 µm ( 201 % ) srt1720 0 . 16 µm ( 781 % ) srt2183 0 . 36 µm ( 296 % ) srt1460 2 . 90 µm ( 447 % ) * Concentration of compound required to increase enzyme activity by 50 % . SIRT1 inhibitors a selective ( vs . other hDaCs ) sirt1 inhibitor , eX527 ( aka sen - 196 ) , was initially reported with an iC 50 ≈ 100 nm in enzymatic assays . 156 eX527 ( 1 µm ) was later shown to increase p53 [ K382 ] acetylation in the presence of etoposide ( but not in the absence ) and had no effect on the expression of p53 target genes , cell viability , or proliferation in various tumor lines . 157 this result was quite unexpected as both sirt1 knockdown and overexpression of catalytically inac - tive sirt1 mutants induce proliferation , apoptosis , and / or Dna damage repair repression in cancer cell lines . 24 , 45 , 97 , 123 , 125 , 126 one possible explanation is that the antitumor effects observed with knockdown are independent of catalytic activity and that the point mutation inactivating the enzyme also disrupts the protein – protein interactions that are indeed responsible for sirt1 activity . p53 is a protein harboring multiple acetyla - tion sites , 158 and it is worthwhile noting that the same lysine residue in p53 ( K382 ) is also targeted by sirt7 , another member of the sirt family . 159 this may reflect a functional redundancy , although the role and activity of sirt7 are poorly established . a new selectivity concept for sirtuin inhibitors in oncology has emerged , based on the observation that multi - isoform sirt inhibitors such as cambinol , 160 sirtinol , 126 salermide , 161 Jgb1741 , 162 suramin analogs , 163 and the tenovins 164 are effective in inducing cancer cell death ( table 3 ) . these observations were recently strengthened by simultaneous rnai - mediated gene silencing of both sirt1 and sirt2 , which potently induced apoptosis in mCf - 7 breast cancer cells , whereas the individual knockdowns were ineffective . 125 in addition , both dual sirt1 / 2 inhibitors sirtinol and salermide , but not eX527 , induced p53 [ K382 ] acetylation and stabilization in mCf7 cells . Pharmacological inhibition of sirt1 and sirt2 is also effica - cious in xenograft models , as exemplified by tenovin - 6 ( arn - 8 melanoma ) 164 and cambinol ( Daudi burkitt lymphoma ) . 160 this lends credence to the belief that dual sirt1 / 2 inhibition may provide therapeutic benefit in cancer . there are an increasing number of publications reporting the discovery of novel dual sirt1 / 2 inhibitors 165 – 167 as well as inhibitors of sirt1 – 3 . 168 it remains to be seen whether dual - or broad - spectrum sirtuin inhibitors may prove to be efficacious and safe in the clinic . concLuSIon it is evident that a great deal has been learned about the biology of sirtuins since their original discovery in yeast . although classified as type iii histone deacetylases , the sir - tuins are both deacetylases and aDP - ribosyltransferases , with substrates that include nonhistone proteins . there is evidence that several sirtuins translocate between subcellular Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1161 table 3 . small - molecule inhibitors of sirt1 JGB - 1741 CAMBINOL SALERMIDE TENOVIN - 6 SPLITOMYCIN EX527 NICOTINAMIDE SIRTINOL Cl NH O NH 2 NH 2 O N O NH N OH O O O NH N OH NH S NH NH O N O OH NH NH S O OH N S NH O JGB - 1741 CAMBINOL SALERMIDE TENOVIN - 6 SPLITOMYCIN EX527 NICOTINAMIDE SIRTINOL Cl NH O NH 2 NH 2 O N O NH N OH O O O NH N OH NH S NH NH O N O OH NH NH S O OH N S NH O SIRT1 IC 50 ( µM ) SIRT2 IC 50 ( µM ) naDh 17 000 205 ( sir2 ) 11 000 205 ( human ) nicotinamide 95 . 1 , 125 130 205 ( hst2 ) 1 . 16 , 125 32 . 3 206 eX527 0 . 16 , 207 0 . 38 , 125 0 . 098 156 48 . 5 , 207 32 . 6 , 125 19 . 6 156 splitomycin ≈100 , 162 * 60 , 146 * 74 208 salermide 76 . 2 125 45 125 sirtinol 131 , 209 37 . 6 125 57 . 7 , 209 103 . 4 125 Cambinol 40 . 7 , 167 57 . 9 , 207 56 160 47 . 9 , 167 40 . 7 , 207 59 160 Jgb1741 15 162 > 100 162 tenovin - 6 21 164 10 164 references listed as superscripts above the iC 50 value . * Yeast sir2 enzyme used ; all others human sirt enzyme . compartments depending on stimuli and form various com - plexes that can be highly regulated by both positive and negative feedback circuits . sirt1 is to date the best studied of the sirtuins . sirt1 is involved in the regulation of meta - bolic , neuronal , immune , and tumor function ( Figs . 1 , 2 ) . however , despite the multitude of data , both molecular and pharmacological , the outcome of selective sirt1 modulation in vivo is still not completely clear . Data from various for - mats explored for both sirt1 enzymatic and cell - based assays suggest great caution should be exercised in assay construction and interpretation of the data . in the case of sirt1 activator assays , the presence of a fluorophore - tagged substrate in certain assays has led to misleading results . it is difficult to reconcile the lack of biological activity for the sole potent and selective sirt1 inhibitor , eX527 , with the opposing results of sirt1 catalytically inactive mutants . moreover , other published inhibitors exert promiscuity with equivocal evidence for inhibition of sirt1 - dependent dea - cetylase activity as the sole mechanism behind the pheno - typic response observed in cancer cells . Perhaps other sirt1 - selective and / or multi - isoform selective compounds will shed light on this situation . advances in structural biol - ogy for the sirtuin family will be quite impactful in guiding further development of isoform - selective and / or broad - spec - trum sirt inhibitors . Co - crystallization with a chemical probe compound ( i . e . , not just apo - protein ) may better aid in understanding the potential binding modes of activators / inhibitors and facilitate medicinal chemistry strategies . it should be noted that although the structures for sirt1 from several lower species have been solved ( table 1 ) , a crystal structure for human sirt1 is yet to be reported . Known sir - tuin isoform crystal structures are outlined and referenced in table 1 . in drug discovery , sirt1 cell - based assays are potentially complicated by the multitude of substrates—that is , which substrate ( s ) is driving the biology / phenotype in question in that specific cell type ? Do they differ between cell types and stimuli ? is there redundancy between sirtuin isoforms ? Comparative data with specific activators / inhibitors and / or molecular tools ( over - expression , knockdown , catalytically inactive mutants ) will be helpful in this regard . having the appropriate animal models will also be critical to understanding sirt1 biology . for oncology , using xenografts in sirt1 - deficient mice with different genetic backgrounds may produce different results ( e . g . , those with inac - tive hiC1 or Pten ; see table 1 ) . animal model selection may affect patient tailoring strategies in oncology if indeed a preferred genetic background lends itself to sirtuin modulation . in summary , the existing data suggest that sirt1 activators may be useful for the treatment of diabetes / metabolic disease , inflammation , and / or neurodegeneration . however , for cancer , the burden of evidence indicates that broad - spectrum sirt1 / 2 inhibitors may provide therapeutic benefit in select tumor types . these opposing approaches bring up many questions , such as whether sirt1 activators will promote cancer ( no evi - dence thus far ) or whether sirt1 ( and sirt2 ) inhibitors will exacerbate metabolic disease , inflammation , and / or neurode - generation ( data equivocal at best ) . more potent and selective compounds will need to be tested in vivo to unequivocally answer these questions . the preponderance of data is indeed compelling enough to justify drug discovery efforts for both sirt1 activators and sirt1 / 2 inhibitors . Stünkel and campbell 1162 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 NCoR PPARy LXR AcCoA - S PGC1α Metabolism UCP2 Lipogenesis Insulin - Sensitivity Neuronal Function Immune Function IRS - 2 α - Secretase Aβ Peptide Neuroprotection Neurite Outgrowth NFκB IL - 8 HIV / Tat AP - 1 Cox2 Inflammation Immunity PTP1B SIRT1 FIg . 1 . Diverse roles of sirt1 in biological pathways . sirt1 is a central regulator with impact on metabolic , neuronal , and immunological functions . sirt1 enhances insulin sensitivity , and aberrant function is associated with the etiology of type 2 diabetes mellitus . in addition , sirt1 has been shown to be neuroprotective and anti - inflammatory , both via deacetylation of nfκb . arrows with diamond - shaped ends show inhibitory action via deacetylation . Tumor Suppressor Function Tumor Promoter Function SIRT1 β - Catenin APC min / + Intestinal Polyps Cell Proliferation BRCA1 mutant AKT mTOR PTEN p53 Cell Survival cMyc CellProliferation HIC1 DBC1 FOXO1 Angiogenesis TIP60 Cell Survival H2AX ~ Ac FIg . 2 . sirt1’s dual roles in cancer . sirt1 functions as a context - dependent tumor suppressor and oncogene . sirt1 has direct repressive activity on a number of cancer - relevant pathways involving mtor , mutated brCa1 , and aPC . however , in the context of mutations ( e . g . , negative regulators such as hiC1 and DbC1 ) , sirt1 activity is enhanced , tipping the balance toward increased cancer cell survival , angiogen - esis , and cell cycle progression . arrows with diamond shaped ends show an inhibitory activity . Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1163 reFerenceS 1 . horio , Y . ; hayashi , t . ; Kuno , a . ; Kunimoto , r . Cellular and molecular effects of sirtuins in health and Disease . Clin . Sci . ( Lond ) . 2011 , 121 ( 5 ) , 191 – 203 . 2 . Cen , Y . ; Youn , D . Y . ; sauve , a . a . advances in Characterization of human sirtuin isoforms : Chemistries , targets and therapeutic applications . Curr . Med . Chem . 2011 , 18 ( 13 ) , 1919 – 1935 . 3 . haigis , m . C . ; sinclair , D . a . mammalian sirtuins : biological insights and Disease relevance . Annu . Rev . Pathol . 2010 , 5 , 253 – 295 . 4 . michishita , e . ; Park , J . Y . ; burneskis , J . m . ; barrett , J . C . ; horikawa , i . evolutionarily Conserved and nonconserved Cellular localizations and functions of human sirt Proteins . Mol . Biol . Cell . 2005 , 16 ( 10 ) , 4623 – 4635 . 5 . north , b . J . ; Verdin , e . interphase nucleo - Cytoplasmic shuttling and localization of sirt2 during mitosis . PLoS One 2007 , 2 ( 8 ) , e784 . 6 . tanno , m . ; sakamoto , J . ; miura , t . ; shimamoto , K . ; horio , Y . nucleocytoplasmic shuttling of the naD + - Dependent histone Deacetylase sirt1 . J . Biol . Chem . 2007 , 282 ( 9 ) , 6823 – 6832 . 7 . tanner , K . g . ; landry , J . ; sternglanz , r . ; Denu , J . m . silent information regulator 2 family of naD - Dependent histone / Protein Deacetylases generates a unique Product , 1 - o - acetyl - aDP - ribose . Proc . Natl . Acad . Sci . U . S . A . 2000 , 97 ( 26 ) , 14178 – 14182 . 8 . borra , m . t . ; langer , m . r . ; slama , J . t . ; Denu , J . m . substrate specificity and Kinetic mechanism of the sir2 family of naD + - Dependent histone / Protein Deacetylases . Biochemistry 2004 , 43 ( 30 ) , 9877 – 9887 . 9 . mahlknecht , u . ; Voelter - mahlknecht , s . fluorescence in situ hybridization and Chromosomal organization of the sirtuin 4 gene ( sirt4 ) in the mouse . Biochem . Biophys . Res . Commun . 2009 , 382 ( 4 ) , 685 – 690 . 10 . Pan , P . W . ; feldman , J . l . ; Devries , m . K . ; Dong , a . ; edwards , a . m . ; Denu , J . m . structure and biochemical functions of sirt6 . J . Biol . Chem . 2011 , 286 ( 16 ) , 14575 – 14587 . 11 . liu , b . ; lin , Y . ; Darwanto , a . ; song , X . ; Xu , g . ; Zhang , K . identification and Characterization of Propionylation at histone h3 lysine 23 in mammalian Cells . J . Biol . Chem . 2009 , 284 ( 47 ) , 32288 – 32295 . 12 . Kaeberlein , m . ; mcVey , m . ; guarente , l . the sir2 / 3 / 4 Complex and sir2 alone Promote longevity in Saccharomyces cerevisiae by two Different mechanisms . Genes Dev . 1999 , 13 ( 19 ) , 2570 – 2580 . 13 . shore , D . ; squire , m . ; nasmyth , K . a . Characterization of two genes required for the Position - effect Control of Yeast mating - type genes . EMBO J . 1984 , 3 ( 12 ) , 2817 – 2823 . 14 . saunders , l . r . ; Verdin , e . sirtuins : Critical regulators at the Crossroads between Cancer and aging . Oncogene 2007 , 26 ( 37 ) , 5489 – 5504 . 15 . imai , s . ; armstrong , C . m . ; Kaeberlein , m . ; guarente , l . transcriptional silencing and longevity Protein sir2 is an naD - Dependent histone Deacetylase . Nature 2000 , 403 ( 6771 ) , 795 – 800 . 16 . Vaquero , a . ; scher , m . ; lee , D . ; erdjument - bromage , h . ; tempst , P . ; reinberg , D . human sirt1 interacts with histone h1 and Promotes formation of facultative heterochromatin . Mol . Cell . 2004 , 16 ( 1 ) , 93 – 105 . 17 . Wang , r . h . ; sengupta , K . ; li , C . ; Kim , h . s . ; Cao , l . ; Xiao , C . ; Kim , s . ; Xu , X . ; Zheng , Y . ; Chilton , b . ; et al . impaired Dna Damage response , genome instability , and tumorigenesis in sirt1 mutant mice . Cancer Cell . 2008 , 14 ( 4 ) , 312 – 323 . 18 . fraga , m . f . ; ballestar , e . ; Villar - garea , a . ; boix - Chornet , m . ; espada , J . ; schotta , g . ; bonaldi , t . ; haydon , C . ; ropero , s . ; Petrie , K . ; et al . loss of acetylation at lys16 and trimethylation at lys20 of histone h4 is a Common hallmark of human Cancer . Nat . Genet . 2005 , 37 ( 4 ) , 391 – 400 . 19 . Dang , W . ; steffen , K . K . ; Perry , r . ; Dorsey , J . a . ; Johnson , f . b . ; shilatifard , a . ; Kaeberlein , m . ; Kennedy , b . K . ; berger , s . l . histone h4 lysine 16 acetylation regulates Cellular lifespan . Nature 2009 , 459 ( 7248 ) , 802 – 807 . 20 . Vempati , r . K . ; Jayani , r . s . ; notani , D . ; sengupta , a . ; galande , s . ; haldar , D . p300 - mediated acetylation of histone h3 lysine 56 functions in Dna Damage response in mammals . J . Biol . Chem . 2010 , 285 ( 37 ) , 28553 – 28564 . 21 . Kong , s . ; Kim , s . J . ; sandal , b . ; lee , s . m . ; gao , b . ; Zhang , D . D . ; fang , D . the type iii histone Deacetylase sirt1 suppresses p300 - medi - ated histone h3 lysine 56 acetylation at bclaf1 Promoter to inhibit t Cell activation . J . Biol . Chem . 2011 , 286 ( 19 ) , 16967 – 16975 . 22 . Zhang , J . ; lee , s . m . ; shannon , s . ; gao , b . ; Chen , W . ; Chen , a . ; Divekar , r . ; mcburney , m . W . ; braley - mullen , h . ; Zaghouani , h . ; et al . the type iii histone Deacetylase sirt1 is essential for maintenance of t Cell tolerance in mice . J . Clin . Invest . 2009 , 119 ( 10 ) , 3048 – 3058 . 23 . sequeira , J . ; boily , g . ; bazinet , s . ; saliba , s . ; he , X . ; Jardine , K . ; Kennedy , C . ; staines , W . ; rousseaux , C . ; mueller , r . ; et al . sirt1 - null mice Develop an autoimmune - like Condition . Exp . Cell . Res . 2008 , 314 ( 16 ) , 3069 – 3074 . 24 . Vaziri , h . ; Dessain , s . K . ; ng eaton , e . ; imai , s . i . ; frye , r . a . ; Pandita , t . K . ; guarente , l . ; Weinberg , r . a . hsir2 ( sirt1 ) functions as an naD - Dependent p53 Deacetylase . Cell 2001 , 107 ( 2 ) , 149 – 159 . 25 . luo , J . ; nikolaev , a . Y . ; imai , s . ; Chen , D . ; su , f . ; shiloh , a . ; guarente , l . ; gu , W . negative Control of p53 by sir2alpha Promotes Cell survival under stress . Cell 2001 , 107 ( 2 ) , 137 – 148 . 26 . Dai , J . m . ; Wang , Z . Y . ; sun , D . C . ; lin , r . X . ; Wang , s . Q . sirt1 interacts with p73 and suppresses p73 - Dependent transcriptional activity . J . Cell . Physiol . 2007 , 210 ( 1 ) , 161 – 166 . 27 . brunet , a . ; sweeney , l . b . ; sturgill , J . f . ; Chua , K . f . ; greer , P . l . ; lin , Y . ; tran , h . ; ross , s . e . ; mostoslavsky , r . ; Cohen , h . Y . ; et al . stress - Dependent regulation of foXo transcription factors by the sirt1 Deacetylase . Science 2004 , 303 ( 5666 ) , 2011 – 2015 . 28 . motta , m . C . ; Divecha , n . ; lemieux , m . ; Kamel , C . ; Chen , D . ; gu , W . ; bultsma , Y . ; mcburney , m . ; guarente , l . mammalian sirt1 represses forkhead transcription factors . Cell 2004 , 116 ( 4 ) , 551 – 563 . 29 . van der horst , a . ; tertoolen , l . g . ; de Vries - smits , l . m . ; frye , r . a . ; medema , r . h . ; burgering , b . m . foXo4 is acetylated upon Peroxide stress and Deacetylated by the longevity Protein hsir2 ( sirt1 ) . J . Biol . Chem . 2004 , 279 ( 28 ) , 28873 – 28879 . 30 . Xiong , s . ; salazar , g . ; Patrushev , n . ; alexander , r . W . foxo1 mediates an autofeedback loop regulating sirt1 expression . J . Biol . Chem . 2011 , 286 ( 7 ) , 5289 – 5299 . 31 . ikenoue , t . ; inoki , K . ; Zhao , b . ; guan , K . l . Pten acetylation modulates its interaction with PDZ Domain . Cancer Res . 2008 , 68 ( 17 ) , 6908 – 6912 . 32 . guarani , V . ; Deflorian , g . ; franco , C . a . ; Kruger , m . ; Phng , l . K . ; bentley , K . ; toussaint , l . ; Dequiedt , f . ; mostoslavsky , r . ; schmidt , m . h . ; et al . acetylation - Dependent regulation of endothelial notch signalling by the sirt1 Deacetylase . Nature 2011 , 473 ( 7346 ) , 234 – 238 . 33 . Zhao , X . ; sternsdorf , t . ; bolger , t . a . ; evans , r . m . ; Yao , t . P . regulation of mef2 by histone Deacetylase 4 - and sirt1 Deacetylase - mediated lysine modifications . Mol . Cell . Biol . 2005 , 25 ( 19 ) , 8456 – 8464 . 34 . Dioum , e . m . ; Chen , r . ; alexander , m . s . ; Zhang , Q . ; hogg , r . t . ; gerard , r . D . ; garcia , J . a . regulation of hypoxia - inducible factor Stünkel and campbell 1164 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 2alpha signaling by the stress - responsive Deacetylase sirtuin 1 . Science 2009 , 324 ( 5932 ) , 1289 – 1293 . 35 . lim , J . h . ; lee , Y . m . ; Chun , Y . s . ; Chen , J . ; Kim , J . e . ; Park , J . W . sirtuin 1 modulates Cellular responses to hypoxia by Deacetylating hypoxia - inducible factor 1alpha . Mol . Cell . 2010 , 38 ( 6 ) , 864 – 878 . 36 . leiser , s . f . ; Kaeberlein , m . a role for sirt1 in the hypoxic response . Mol . Cell . 2010 , 38 ( 6 ) , 779 – 780 . 37 . muth , V . ; nadaud , s . ; grummt , i . ; Voit , r . acetylation of taf ( i ) 68 , a subunit of tif - ib / sl1 , activates rna Polymerase i transcription . EMBO J . 2001 , 20 ( 6 ) , 1353 – 1362 . 38 . Ponugoti , b . ; Kim , D . h . ; Xiao , Z . ; smith , Z . ; miao , J . ; Zang , m . ; Wu , s . Y . ; Chiang , C . m . ; Veenstra , t . D . ; Kemper , J . K . sirt1 Deacetylates and inhibits srebP - 1C activity in regulation of hepatic lipid metabolism . J . Biol . Chem . 2010 , 285 ( 44 ) , 33959 – 33970 . 39 . firestein , r . ; blander , g . ; michan , s . ; oberdoerffer , P . ; ogino , s . ; Campbell , J . ; bhimavarapu , a . ; luikenhuis , s . ; de Cabo , r . ; fuchs , C . ; et al . the sirt1 Deacetylase suppresses intestinal tumorigenesis and Colon Cancer growth . PloS One 2008 , 3 ( 4 ) , e2020 . 40 . Yeung , f . ; hoberg , J . e . ; ramsey , C . s . ; Keller , m . D . ; Jones , D . r . ; frye , r . a . ; mayo , m . W . modulation of nf - kappab - Dependent transcription and Cell survival by the sirt1 Deacetylase . EMBO J . 2004 , 23 ( 12 ) , 2369 – 2380 . 41 . schug , t . t . ; Xu , Q . ; gao , h . ; Peres - da - silva , a . ; Draper , D . W . ; fessler , m . b . ; Purushotham , a . ; li , X . myeloid Deletion of sirt1 induces inflammatory signaling in response to environmental stress . Mol . Cell . Biol . 2010 , 30 ( 19 ) , 4712 – 4721 . 42 . rodgers , J . t . ; lerin , C . ; haas , W . ; gygi , s . P . ; spiegelman , b . m . ; Puigserver , P . nutrient Control of glucose homeostasis through a Complex of PgC - 1alpha and sirt1 . Nature 2005 , 434 ( 7029 ) , 113 – 118 . 43 . nakahata , Y . ; Kaluzova , m . ; grimaldi , b . ; sahar , s . ; hirayama , J . ; Chen , D . ; guarente , l . P . ; sassone - Corsi , P . the naD + - Dependent Deacetylase sirt1 modulates CloCK - mediated Chromatin remodeling and Circadian Control . Cell 2008 , 134 ( 2 ) , 329 – 340 . 44 . asher , g . ; gatfield , D . ; stratmann , m . ; reinke , h . ; Dibner , C . ; Kreppel , f . ; mostoslavsky , r . ; alt , f . W . ; schibler , u . sirt1 regulates Circadian Clock gene expression through Per2 Deacetylation . Cell 2008 , 134 ( 2 ) , 317 – 328 . 45 . Jeong , J . ; Juhn , K . ; lee , h . ; Kim , s . h . ; min , b . h . ; lee , K . m . ; Cho , m . h . ; Park , g . h . ; lee , K . h . sirt1 Promotes Dna repair activity and Deacetylation of Ku70 . Exp . Mol . Med . 2007 , 39 ( 1 ) , 8 – 13 . 46 . fan , W . ; luo , J . sirt1 regulates uV - induced Dna repair through Deacetylating XPa . Mol . Cell . 2010 , 39 ( 2 ) , 247 – 258 . 47 . Kume , s . ; haneda , m . ; Kanasaki , K . ; sugimoto , t . ; araki , s . ; isshiki , K . ; isono , m . ; uzu , t . ; guarente , l . ; Kashiwagi , a . ; et al . sirt1 inhibits transforming growth factor beta - induced apoptosis in glomerular mesangial Cells via smad7 Deacetylation . J . Biol . Chem . 2007 , 282 ( 1 ) , 151 – 158 . 48 . Zhang , Y . ; Zhang , m . ; Dong , h . ; Yong , s . ; li , X . ; olashaw , n . ; Kruk , P . a . ; Cheng , J . Q . ; bai , W . ; Chen , J . ; et al . Deacetylation of Cortactin by sirt1 Promotes Cell migration . Oncogene 2009 , 28 ( 3 ) , 445 – 460 . 49 . Zhang , J . the Direct involvement of sirt1 in insulin - induced insulin receptor substrate - 2 tyrosine Phosphorylation . J . Biol . Chem . 2007 , 282 ( 47 ) , 34356 – 34364 . 50 . li , Y . ; Xu , W . ; mcburney , m . W . ; longo , V . D . sirt1 inhibition reduces igf - i / irs - 2 / ras / erK1 / 2 signaling and Protects neurons . Cell . Metab . 2008 , 8 ( 1 ) , 38 – 48 . 51 . min , s . W . ; Cho , s . h . ; Zhou , Y . ; schroeder , s . ; haroutunian , V . ; seeley , W . W . ; huang , e . J . ; shen , Y . ; masliah , e . ; mukherjee , C . ; et al . acetylation of tau inhibits its Degradation and Contributes to tauopathy . Neuron 2010 , 67 ( 6 ) , 953 – 966 . 52 . Yamamori , t . ; Dericco , J . ; naqvi , a . ; hoffman , t . a . ; mattagajasingh , i . ; Kasuno , K . ; Jung , s . b . ; Kim , C . s . ; irani , K . sirt1 Deacetylates aPe1 and regulates Cellular base excision repair . Nucleic Acids Res . 2010 , 38 ( 3 ) , 832 – 845 . 53 . Pediconi , n . ; guerrieri , f . ; Vossio , s . ; bruno , t . ; belloni , l . ; schinzari , V . ; scisciani , C . ; fanciulli , m . ; levrero , m . hsirt1 - Dependent regulation of the PCaf - e2f1 - p73 apoptotic Pathway in response to Dna Damage . Mol . Cell . Biol . 2009 , 29 ( 8 ) , 1989 – 1998 . 54 . Wang , J . ; Chen , J . sirt1 regulates autoacetylation and histone acetyltransferase activity of tiP60 . J . Biol . Chem . 2010 , 285 ( 15 ) , 11458 – 11464 . 55 . Pagans , s . ; Pedal , a . ; north , b . J . ; Kaehlcke , K . ; marshall , b . l . ; Dorr , a . ; hetzer - egger , C . ; henklein , P . ; frye , r . ; mcburney , m . W . ; et al . sirt1 regulates hiV transcription via tat Deacetylation . PLoS Biol . 2005 , 3 ( 2 ) , e41 . 56 . bouras , t . ; fu , m . ; sauve , a . a . ; Wang , f . ; Quong , a . a . ; Perkins , n . D . ; hay , r . t . ; gu , W . ; Pestell , r . g . sirt1 Deacetylation and repression of p300 involves lysine residues 1020 / 1024 within the Cell Cycle regulatory Domain 1 . J . Biol . Chem . 2005 , 280 ( 11 ) , 10264 – 10276 . 57 . Vaquero , a . ; scher , m . ; erdjument - bromage , h . ; tempst , P . ; serrano , l . ; reinberg , D . sirt1 regulates the histone methyl - transferase suV39h1 during heterochromatin formation . Nature 2007 , 450 ( 7168 ) , 440 – 444 . 58 . hallows , W . C . ; lee , s . ; Denu , J . m . sirtuins Deacetylate and activate mammalian acetyl - Coa synthetases . Proc . Natl . Acad . Sci . U . S . A . 2006 , 103 ( 27 ) , 10230 – 10235 . 59 . north , b . J . ; sinclair , D . a . sirtuins : a Conserved Key unlocking aceCs activity . Trends Biochem . Sci . 2007 , 32 ( 1 ) , 1 – 4 . 60 . han , l . ; Zhou , r . ; niu , J . ; mcnutt , m . a . ; Wang , P . ; tong , t . sirt1 is regulated by a PParγ - sirt1 negative feedback loop associated with senescence . Nucleic Acids Res . 2010 , 38 ( 21 ) , 7458 – 7471 . 61 . Kim , m . Y . ; Woo , e . m . ; Chong , Y . t . ; homenko , D . r . ; Kraus , W . l . acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the Deoxyribonucleic acid binding and transactiva - tion activities of the receptor . Mol . Endocrinol . 2006 , 20 ( 7 ) , 1479 – 1493 . 62 . fu , m . ; liu , m . ; sauve , a . a . ; Jiao , X . ; Zhang , X . ; Wu , X . ; Powell , m . J . ; Yang , t . ; gu , W . ; avantaggiati , m . l . ; et al . hormonal Control of androgen receptor function through sirt1 . Mol . Cell . Biol . 2006 , 26 ( 21 ) , 8122 – 8135 . 63 . li , X . ; Zhang , s . ; blander , g . ; tse , J . g . ; Krieger , m . ; guarente , l . sirt1 Deacetylates and Positively regulates the nuclear receptor lXr . Mol . Cell . 2007 , 28 ( 1 ) , 91 – 106 . 64 . blander , g . ; olejnik , J . ; Krzymanska - olejnik , e . ; mcDonagh , t . ; haigis , m . ; Yaffe , m . b . ; guarente , l . sirt1 shows no substrate specificity in Vitro . J . Biol . Chem . 2005 , 280 ( 11 ) , 9780 – 9785 . 65 . hisahara , s . ; Chiba , s . ; matsumoto , h . ; tanno , m . ; Yagi , h . ; shimohama , s . ; sato , m . ; horio , Y . histone Deacetylase sirt1 modulates neuronal Differentiation by its nuclear translocation . Proc . Natl . Acad . Sci . U . S . A . 2008 , 105 ( 40 ) , 15599 – 15604 . 66 . sugino , t . ; maruyama , m . ; tanno , m . ; Kuno , a . ; houkin , K . ; horio , Y . Protein Deacetylase sirt1 in the Cytoplasm Promotes nerve growth Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1165 factor - induced neurite outgrowth in PC12 Cells . FEBS Lett . 2010 , 584 ( 13 ) , 2821 – 2826 . 67 . holness , m . J . ; Caton , P . W . ; sugden , m . C . acute and long - term nutrient - led modifications of gene expression : Potential role of sirt1 as a Central Co - ordinator of short and longer - term Programming of tissue function . Nutrition 2010 , 26 ( 5 ) , 491 – 501 . 68 . sasaki , t . ; Kitamura , t . roles of foxo1 and sirt1 in the Central regulation of food intake . Endocr . J . 2010 , 57 ( 11 ) , 939 – 946 . 69 . bellet , m . m . ; sassone - Corsi , P . mammalian Circadian Clock and metabolism : the epigenetic link . J . Cell . Sci . 2010 , 123 ( Pt 22 ) , 3837 – 3848 . 70 . Yang , t . ; fu , m . ; Pestell , r . ; sauve , a . a . sirt1 and endocrine signaling . Trends Endocrinol . Metab . 2006 , 17 ( 5 ) , 186 – 191 . 71 . Dominy , J . e . , Jr . ; lee , Y . ; gerhart - hines , Z . ; Puigserver , P . nutrient - Dependent regulation of PgC - 1alpha’s acetylation state and metabolic function through the enzymatic activities of sirt1 / gCn5 . Biochim . Biophys . Acta 2010 , 1804 ( 8 ) , 1676 – 1683 . 72 . Zhang , t . ; Kraus , W . l . sirt1 - Dependent regulation of Chromatin and transcription : linking naD ( + ) metabolism and signaling to the Control of Cellular functions . Biochim . Biophys . Acta 2010 , 1804 ( 8 ) , 1666 – 1675 . 73 . li , Y . ; Xu , s . ; giles , a . ; nakamura , K . ; lee , J . W . ; hou , X . ; Donmez , g . ; li , J . ; luo , Z . ; Walsh , K . ; et al . hepatic overexpression of sirt1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver . FASEB J . 2011 , 25 ( 5 ) , 1664 – 1679 . 74 . sun , C . ; Zhang , f . ; ge , X . ; Yan , t . ; Chen , X . ; shi , X . ; Zhai , Q . sirt1 improves insulin sensitivity under insulin - resistant Conditions by repressing PtP1b . Cell . Metab . 2007 , 6 ( 4 ) , 307 – 319 . 75 . bordone , l . ; motta , m . C . ; Picard , f . ; robinson , a . ; Jhala , u . s . ; apfeld , J . ; mcDonagh , t . ; lemieux , m . ; mcburney , m . ; szilvasi , a . ; et al . sirt1 regulates insulin secretion by repressing uCP2 in Pancreatic beta Cells . PLoS Biol . 2006 , 4 ( 2 ) , e31 . 76 . haigis , m . C . ; guarente , l . P . mammalian sirtuins : emerging roles in Physiology , aging , and Calorie restriction . Genes Dev . 2006 , 20 ( 21 ) , 2913 – 2921 . 77 . liang , f . ; Kume , s . ; Koya , D . sirt1 and insulin resistance . Nat . Rev . Endocrinol . 2009 , 5 ( 7 ) , 367 – 373 . 78 . Chen , J . ; Zhou , Y . ; mueller - steiner , s . ; Chen , l . f . ; Kwon , h . ; Yi , s . ; mucke , l . ; gan , l . sirt1 Protects against microglia - Dependent amyloid - beta toxicity through inhibiting nf - kappab signaling . J . Biol . Chem . 2005 , 280 ( 48 ) , 40364 – 40374 . 79 . Qin , W . ; Yang , t . ; ho , l . ; Zhao , Z . ; Wang , J . ; Chen , l . ; Zhao , W . ; thiyagarajan , m . ; macgrogan , D . ; rodgers , J . t . ; et al . neuronal sirt1 activation as a novel mechanism underlying the Prevention of alzheimer Disease amyloid neuropathology by Calorie restriction . J . Biol . Chem . 2006 , 281 ( 31 ) , 21745 – 21754 . 80 . Donmez , g . ; Wang , D . ; Cohen , D . e . ; guarente , l . sirt1 suppresses beta - amyloid Production by activating the alpha - secretase gene aDam10 . Cell 2010 , 142 ( 2 ) , 320 – 332 . 81 . Wang , J . ; fivecoat , h . ; ho , l . ; Pan , Y . ; ling , e . ; Pasinetti , g . m . the role of sirt1 : at the Crossroad between Promotion of longevity and Protection against alzheimer’s Disease neuropathology . Biochim . Biophys . Acta 2010 , 1804 ( 8 ) , 1690 – 1694 . 82 . Kim , D . ; nguyen , m . D . ; Dobbin , m . m . ; fischer , a . ; sananbenesi , f . ; rodgers , J . t . ; Delalle , i . ; , baur , J . a . ; sui , g . ; armour , s . m . ; et al . sirt1 Deacetylase Protects against neurodegeneration in models for alzheimer’s Disease and amyotrophic lateral sclerosis . EMBO J . 2007 , 26 ( 13 ) , 3169 – 3179 . 83 . Yang , Z . ; Kahn , b . b . ; shi , h . ; Xue , b . Z . macrophage alpha1 amP - activated Protein Kinase ( alpha1amPK ) antagonizes fatty acid – induced inflammation through sirt1 . J . Biol . Chem . 2010 , 285 ( 25 ) , 19051 – 19059 . 84 . rajendrasozhan , s . ; Yang , s . r . ; Kinnula , V . l . ; rahman , i . sirt1 , an antiinflammatory and antiaging Protein , is Decreased in lungs of Patients with Chronic obstructive Pulmonary Disease . Am . J . Respir . Crit . Care Med . 2008 , 177 ( 8 ) , 861 – 870 . 85 . Zhang , r . ; Chen , h . Z . ; liu , J . J . ; Jia , Y . Y . ; Zhang , Z . Q . ; Yang , r . f . ; Zhang , Y . ; Xu , J . ; Wei , Y . s . ; liu , D . P . ; et al . sirt1 suppresses activator Protein - 1 transcriptional activity and Cyclooxygenase - 2 expression in macrophages . J . Biol . Chem . 2010 , 285 ( 10 ) , 7097 – 7110 . 86 . Planavila , a . ; iglesias , r . ; giralt , m . ; Villarroya , f . sirt1 acts in association with PPar { alpha } to Protect the heart from hypertrophy , metabolic Dysregulation , and inflammation . Cardiovasc . Res . 2011 , 90 ( 2 ) , 276 – 284 . 87 . Zhang , Z . ; lowry , s . f . ; guarente , l . ; haimovich , b . roles of sirt1 in the acute and restorative Phases following induction of inflammation . J . Biol . Chem . 2010 , 285 ( 53 ) , 41391 – 41401 . 88 . liu , t . f . ; Yoza , b . K . ; el gazzar , m . ; Vachharajani , V . t . ; mcCall , C . e . naD + - Dependent sirt1 Deacetylase Participates in epigenetic reprogramming during endotoxin tolerance . J . Biol . Chem . 2011 , 286 ( 11 ) , 9856 – 9864 . 89 . Kwon , h . s . ; brent , m . m . ; getachew , r . ; Jayakumar , P . ; Chen , l . f . ; schnoelzer , m . ; mcburney , m . W . ; marmorstein , r . ; greene , W . C . ; ott , m . human immunodeficiency Virus type 1 tat Protein inhibits the sirt1 Deacetylase and induces t Cell hyperactivation . Cell Host Microbe 2008 , 3 ( 3 ) , 158 – 167 . 90 . beier , u . h . ; Wang , l . ; bhatti , t . r . ; liu , Y . ; han , r . , ge , g . ; hancock , W . W . sirtuin - 1 targeting Promotes foxp3 + t - regulatory Cell function and Prolongs allograft survival . Mol . Cell . Biol . 2011 , 31 ( 5 ) , 1022 – 1029 . 91 . Wang , b . ; hasan , m . K . ; alvarado , e . ; Yuan , h . ; Wu , h . ; Chen , W . Y . namPt overexpression in Prostate Cancer and its Contribution to tumor Cell survival and stress response . Oncogene 2011 , 30 ( 8 ) , 907 – 921 . 92 . Chen , J . ; Zhang , b . ; Wong , n . ; lo , a . W . ; to , K . f . ; Chan , a . W . ; ng , m . h . ; ho , C . Y . ; Cheng , s . h . ; lai , P . b . ; et al . sirtuin 1 is upregulated in a subset of hepatocellular Carcinomas Where it is essential for telomere maintenance and tumor Cell growth . Cancer Res . 2011 , 71 ( 12 ) , 4138 – 4149 . 93 . Jung - hynes , b . ; nihal , m . ; Zhong , W . ; ahmad , n . role of sirtuin histone Deacetylase sirt1 in Prostate Cancer : a target for Prostate Cancer management via its inhibition ? J . Biol . Chem . 2009 , 284 ( 6 ) , 3823 – 3832 . 94 . Jang , K . Y . ; Kim , K . s . ; hwang , s . h . ; Kwon , K . s . ; Kim , K . r . ; Park , h . s . ; Park , b . h . ; Chung , m . J . ; Kang , m . J . ; lee , D . g . ; et al . expression and Prognostic significance of sirt1 in ovarian epithelial tumours . Pathology 2009 , 41 ( 4 ) , 366 – 371 . 95 . Cha , e . J . ; noh , s . J . ; Kwon , K . s . ; Kim , C . Y . ; Park , b . h . ; Park , h . s . ; lee , h . ; Chung , m . J . ; Kang , m . J . ; et al . expression of DbC1 and sirt1 is associated with Poor Prognosis of gastric Carcinoma . Clin . Cancer Res . 2009 , 15 ( 13 ) , 4453 – 4459 . 96 . nosho , K . ; shima , K . ; irahara , n . ; Kure , s . ; firestein , r . ; baba , Y . ; toyoda , s . ; Chen , l . ; hazra , a . ; giovannucci , e . l . ; et al . sirt1 histone Deacetylase expression is associated with microsatellite instability and Cpg island methylator Phenotype in Colorectal Cancer . Mod . Pathol . 2009 , 22 ( 7 ) , 922 – 932 . Stünkel and campbell 1166 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 97 . nihal , m . ; ndiaye , m . ; Wood , g . s . ; ahmad , n . in Role of Sirt1 Histone Deacetylase in Melanoma : A Target for Melanoma Management via Its Inhibition , Proceedings of the 102nd annual meeting of the aaCr , orlando , fl , apr 2 – 6 , 2011 ; abstract 1647 . 98 . hoffmann , m . J . ; engers , r . ; florl , a . r . ; otte , a . P . ; muller , m . ; schulz , W . a . expression Changes in eZh2 , but not in bmi - 1 , sirt1 , Dnmt1 or Dnmt3b are associated with Dna methylation Changes in Prostate Cancer . Cancer Biol . Ther . 2007 , 6 ( 9 ) , 1403 – 1412 . 99 . Kabra , n . ; li , Z . ; Chen , l . ; li , b . ; Zhang , X . ; Wang , C . ; Yeatman , t . ; Coppola , D . ; Chen , J . sirt1 is an inhibitor of Proliferation and tumor formation in Colon Cancer . J . Biol . Chem . 2009 , 284 ( 27 ) , 18210 – 18217 . 100 . herranz , D . ; serrano , m . sirt1 : recent lessons from mouse models . Nat . Rev . Cancer 2010 , 10 ( 12 ) , 819 – 823 . 101 . boily , g . ; he , X . h . ; Pearce , b . ; Jardine , K . ; mcburney , m . W . sirt1 - null mice Develop tumors at normal rates but are Poorly Protected by resveratrol . Oncogene 2009 , 28 ( 32 ) , 2882 – 2893 . 102 . Powell , m . J . ; Casimiro , m . C . ; Cordon - Cardo , C . ; he , X . ; Yeow , W . s . ; Wang , C . ; mcCue , P . a . ; mcburney , m . W . ; Pestell , r . g . Disruption of a sirt1 - Dependent autophagy Checkpoint in the Prostate results in Prostatic intraepithelial neoplasia lesion formation . Cancer Res . 2011 , 71 ( 3 ) , 964 – 975 . 103 . ming , m . ; shea , C . r . ; guo , X . ; li , X . ; soltani , K . ; han , W . ; he , Y . Y . regulation of global genome nucleotide excision repair by sirt1 through Xeroderma Pigmentosum C . Proc . Natl . Acad . Sci . U . S . A . 2010 , 107 ( 52 ) , 22623 – 22628 . 104 . Yuan , Z . ; seto , e . a functional link between sirt1 Deacetylase and nbs1 in Dna Damage response . Cell Cycle 2007 , 6 ( 23 ) , 2869 – 2871 . 105 . ghosh , h . s . ; mcburney , m . ; robbins , P . D . sirt1 negatively regulates the mammalian target of rapamycin . PLoS One 2010 , 5 ( 2 ) , e9199 . 106 . back , J . h . ; rezvani , h . r . ; Zhu , Y . ; guyonnet - Duperat , V . ; athar , m . ; ratner , D . ; Kim , a . l . Cancer Cell survival following Dna Damage - mediated Premature senescence is regulated by mammalian target of rapamycin ( mtor ) - Dependent inhibition of sirtuin 1 . J . Biol . Chem . 2011 , 286 ( 21 ) , 19100 – 19108 . 107 . Xiang , t . ; Jia , Y . ; sherris , D . ; li , s . ; Wang , h . ; lu , D . ; Yang , Q . targeting the akt / mtor Pathway in brca1 - Deficient Cancers . Oncogene 2011 , 30 ( 21 ) , 2443 – 2450 . 108 . Wang , r . h . ; Zheng , Y . ; Kim , h . s . ; Xu , X . ; Cao , l . , luhasen , t . ; lee , m . h . ; Xiao , C . ; Vassilopoulos , a . ; Chen , W . ; et al . interplay among brCa1 , sirt1 , and survivin during brCa1 - associated tumorigenesis . Mol . Cell 2008 , 32 ( 1 ) , 11 – 20 . 109 . lu , r . ; bian , f . ; Zhang , X . ; Qi , h . ; Chuang , e . Y . , et al . the beta - Catenin / tcf4 / survivin signaling maintains a less Differentiated Phenotype and high Proliferative Capacity of human Corneal epithelial Progenitor Cells . Int . J . Biochem . Cell . Biol . 2011 , 43 ( 5 ) , 751 – 759 . 110 . holloway , K . r . ; Calhoun , t . n . ; saxena , m . ; metoyer , C . f . ; Kandler , e . f . ; rivera , C . a . ; Pruitt , K . sirt1 regulates Dishevelled Proteins and Promotes transient and Constitutive Wnt signaling . Proc . Natl . Acad . Sci . U . S . A . 2010 , 107 ( 20 ) , 9216 – 9221 . 111 . Papp , b . ; Plath , K . reprogramming to Pluripotency : stepwise resetting of the epigenetic landscape . Cell . Res . 2011 , 21 ( 3 ) , 486 – 501 . 112 . Yuan , J . ; minter - Dykhouse , K . ; lou , Z . a c - myc - sirt1 feedback loop regulates Cell growth and transformation . J . Cell Biol . 2009 , 185 ( 2 ) , 203 – 211 . 113 . hayashi , m . ; tokuchi , Y . ; hashimoto , t . ; hayashi , s . ; nishida , K . ; ishikawa , i . ; nakagawa , K . ; tsuchiya , s . ; okamura , s . ; tsuchiya , e . reduced hiC - 1 gene expression in non - small Cell lung Cancer and its Clinical significance . Anticancer Res . 2001 , 21 ( 1b ) , 535 – 540 . 114 . fujii , h . ; biel , m . a . ; Zhou , W . ; Weitzman , s . a . ; baylin , s . b . ; gabrielson , e . methylation of the hiC - 1 Candidate tumor suppressor gene in human breast Cancer . Oncogene 1998 , 16 ( 16 ) , 2159 – 2164 . 115 . Chen , W . Y . ; Wang , D . h . ; Yen , r . C . ; luo , J . ; gu , W . ; baylin , s . b . tumor suppressor hiC1 Directly regulates sirt1 to modulate p53 - Dependent Dna - Damage responses . Cell 2005 , 123 ( 3 ) , 437 – 448 . 116 . tseng , r . C . ; lee , C . C . ; hsu , h . s . ; tzao , C . ; Wang , Y . C . Distinct hiC1 - sirt1 - p53 loop Deregulation in lung squamous Carcinoma and adenocarcinoma Patients . Neoplasia 2009 , 11 ( 8 ) , 763 – 770 . 117 . mohammad , h . P . ; Zhang , W . ; Prevas , h . s . ; leadem , b . r . ; Zhang , m . ; herman , J . g . ; hooker , C . m . ; Watkins , D . n . ; Karim , b . ; huso , D . l . ; et al . loss of a single hic1 allele accelerates Polyp formation in apc ( Delta716 ) mice . Oncogene 2011 , 30 ( 23 ) , 2659 – 2669 . 118 . marshall , g . m . ; liu , P . Y ; gherardi , s . ; scarlett , C . J . ; bedalov , a . ; Xu , n . ; iraci , n . ; Valli , e . ; ling , D . ; thomas , W . ; van bekkum , m . ; sekyere , e . ; Jankowski , K . ; trahair , t . ; mackenzie , K . l . ; haber , m . ; norris , m . D . ; biankin , a . V . ; Perini , g . ; liu , t . , sirt1 Promotes n - myc oncogenesis through a Positive feedback loop involving the effects of mKP3 and erK on n - myc Protein stability . PLoS Genet 2011 , 7 ( 6 ) , e1002135 . 119 . serrano , m . in SIRT1 Transgenic and Cancer Models , Proceedings of the 102nd annual meeting of the aaCr , orlando , fl , apr 2 – 6 , 2011 ; Presentation sY11 - 03 . 120 . olmos , Y . ; brosens , J . J . ; lam , e . W . interplay between sirt Proteins and tumour suppressor transcription factors in Chemotherapeutic resistance of Cancer . Drug Resist . Updat . 2011 , 14 ( 1 ) , 35 – 44 . 121 . eades , g . ; Yao , Y . ; Yang , m . ; Zhang , Y . ; Chumsri , s . ; Zhou , Q . mir - 200a regulates sirt1 and emt - like transformation in mammary epithelial Cells . J . Biol . Chem . 2011 , 286 ( 29 ) , 25992 – 26002 . 122 . inoue , Y . ; iemura , s . ; natsume , t . ; miyazawa , K . ; imamura , t . suppression of p53 activity through the Cooperative action of ski and histone Deacetylase sirt1 . J . Biol . Chem . 2011 , 286 ( 8 ) , 6311 – 6320 . 123 . ford , J . ; Jiang , m . ; milner , J . Cancer - specific functions of sirt1 enable human epithelial Cancer Cell growth and survival . Cancer Res . 2005 , 65 ( 22 ) , 10457 – 10463 . 124 . stenzinger , a . ; goppert , b . ; Kamphues , C . ; sinn , b . ; bahra , m . ; neuhaus , P . ; Weichert , W . , sirt1 overexpression in pancreatic adeno - carcinomas correlates with shortened patient survival and small mole - cule inhibition as well as target knockdown of sirt1 induces growth arrest and apoptosis in pancreatic cancer cells . 102nd annual meeting of the aaCr 2011 , abstract 1624 . 125 . Peck , b . ; Chen , C . Y . ; ho , K . K . ; Di fruscia , P . ; myatt , s . s . ; Coombes , r . C . ; fuchter , m . J . ; hsiao , C . D . ; lam , e . W . sirt inhibitors induce Cell Death and p53 acetylation through targeting both sirt1 and sirt2 . Mol . Cancer Ther . 2010 , 9 ( 4 ) , 844 – 855 . 126 . ota , h . ; tokunaga , e . ; Chang , K . ; hikasa , m . ; iijima , K . ; eto , m . ; Kozaki , K . ; akishita , m . ; ouchi , Y . ; Kaneki , m . ; et al . sirt1 inhibitor , sirtinol , induces senescence - like growth arrest with attenuated ras - maPK signaling in human Cancer Cells . Oncogene 2006 , 25 ( 2 ) , 176 – 185 . 127 . o’hagan , h . m . ; mohammad , h . P . ; baylin , s . b . Double strand breaks Can initiate gene silencing and sirt1 - Dependent onset of Dna methylation in an exogenous Promoter Cpg island . PLoS Genet . 2008 , 4 ( 8 ) , e1000155 . 128 . Kuzmichev , a . ; margueron , r . ; Vaquero , a . ; Preissner , t . s . ; scher , m . ; Kirmizis , a . ; ouyang , X . ; brockdorff , n . ; abate - shen , C . ; farnham , P . ; reinberg , D . Composition and histone substrates of Polycomb Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1167 repressive group Complexes Change during Cellular Differentiation . Proc . Natl . Acad . Sci . U . S . A . 2005 , 102 ( 6 ) , 1859 – 1864 . 129 . sun , Y . ; Jiang , X . ; Price , b . D . tip60 : Connecting Chromatin to Dna Damage signaling . Cell Cycle 2010 , 9 ( 5 ) , 930 – 936 . 130 . ikura , t . ; ogryzko , V . V . ; grigoriev , m . ; groisman , r . ; Wang , J . ; horikoshi , m . ; scully , r . ; Qin , J . ; nakatani , Y . involvement of the tiP60 histone acetylase Complex in Dna repair and apoptosis . Cell 2000 , 102 ( 4 ) , 463 – 473 . 131 . Yamagata , K . ; Kitabayashi , i . sirt1 Physically interacts with tip60 and negatively regulates tip60 - mediated acetylation of h2aX . Biochem . Biophys . Res . Commun . 2009 , 390 ( 4 ) , 1355 – 1360 . 132 . Wang , C . ; Chen , l . ; hou , X . ; li , Z . ; Kabra , n . ; ma , Y . ; nemoto , s . ; finkel , t . ; gu , W . ; Cress , W . D . ; et al . interactions between e2f1 and sirt1 regulate apoptotic response to Dna Damage . Nat . Cell . Biol . 2006 , 8 ( 9 ) , 1025 – 1031 . 133 . Potente , m . ; ghaeni , l . ; baldessari , D . ; mostoslavsky , r . ; rossig , l . ; Dequiedt , f . ; haendeler , J . ; mione , m . ; Dejana , e . ; alt , f . W . ; et al . sirt1 Controls endothelial angiogenic functions during Vascular growth . Genes Dev . 2007 , 21 ( 20 ) , 2644 – 2658 . 134 . li , Y . ; tondravi , m . ; liu , J . ; smith , e . ; haudenschild , C . C . ; Kaczmarek , m . ; Zhan , X . Cortactin Potentiates bone metastasis of breast Cancer Cells . Cancer Res . 2001 , 61 ( 18 ) , 6906 – 6911 . 135 . luo , m . l . ; shen , X . m . ; Zhang , Y . ; Wei , f . ; Xu , X . ; sun , Y . t . ; Zhan , Q . m . ; Wu , m . ; Wang , m . r . amplification and overexpression of Cttn ( ems1 ) Contribute to the metastasis of esophageal squamous Cell Carcinoma by Promoting Cell migration and anoikis resistance . Cancer Res . 2006 , 66 ( 24 ) , 11690 – 11699 . 136 . marcotte , P . a . ; richardson , P . l . ; guo , J . ; barrett , l . W . ; Xu , n . ; gunasekera , a . ; glaser , K . b . fluorescence assay of sirt Protein Deacetylases using an acetylated Peptide substrate and a secondary trypsin reaction . Anal . Biochem . 2004 , 332 ( 1 ) , 90 – 99 . 137 . bitterman , K . J . ; anderson , r . m . ; Cohen , h . Y . ; latorre - esteves , m . ; sinclair , D . a . inhibition of silencing and accelerated aging by nicotinamide , a Putative negative regulator of Yeast sir2 and human sirt1 . J . Biol . Chem . 2002 , 277 ( 47 ) , 45099 – 45107 . 138 . feng , Y . ; Wu , J . ; Chen , l . ; luo , C . ; shen , X . ; Chen , K . ; Jiang , h . ; liu , D . a fluorometric assay of sirt1 Deacetylation activity through Quantification of nicotinamide adenine Dinucleotide . Anal . Biochem . 2009 , 395 ( 2 ) , 205 – 210 . 139 . Wegener , D . ; hildmann , C . ; riester , D . ; schwienhorst , a . improved fluorogenic histone Deacetylase assay for high - throughput - screening applications . Anal . Biochem . 2003 , 321 ( 2 ) , 202 – 208 . 140 . liu , Y . ; gerber , r . ; Wu , J . ; tsuruda , t . ; mcCarter , J . D . high - throughput assays for sirtuin enzymes : a microfluidic mobility shift assay and a bioluminescence assay . Anal . Biochem . 2008 , 378 ( 1 ) , 53 – 59 . 141 . milne , J . C . ; lambert , P . D . ; schenk , s . ; Carney , D . P . ; smith , J . J . ; gagne , D . J . ; Jin , l . ; boss , o . ; Perni , r . b . ; Vu , C . b . ; et al . small molecule activators of sirt1 as therapeutics for the treatment of type 2 Diabetes . Nature 2007 , 450 ( 7170 ) , 712 – 716 . 142 . rye , P . t . ; frick , l . e . ; ozbal , C . C . ; lamarr , W . a . advances in label - free screening approaches for studying histone acetyltransferases . J . Biomol . Screen . 2011 , 16 ( 10 ) , 1186 – 1195 . 143 . fan , Y . ; hense , m . ; ludewig , r . ; Weisgerber , C . ; scriba , g . K . Capillary electrophoresis - based sirtuin assay using non - Peptide substrates . J . Pharm . Biomed . Anal . 2011 , 54 ( 4 ) , 772 – 778 . 144 . Jackson , m . D . ; Denu , J . m . structural identification of 2′ - and 3′ - o - acetyl - aDP - ribose as novel metabolites Derived from the sir2 family of beta - naD + - Dependent histone / Protein Deacetylases . J . Biol . Chem . 2002 , 277 ( 21 ) , 18535 – 18544 . 145 . grozinger , C . m . ; Chao , e . D . ; blackwell , h . e . ; moazed , D . ; schreiber , s . l . identification of a Class of small molecule inhibitors of the sirtuin family of naD - Dependent Deacetylases by Phenotypic screening . J . Biol . Chem . 2001 , 276 ( 42 ) , 38837 – 38843 . 146 . bedalov , a . ; gatbonton , t . ; irvine , W . P . ; gottschling , D . e . ; simon , J . a . identification of a small molecule inhibitor of sir2p . Proc . Natl . Acad . Sci . U . S . A . 2001 , 98 ( 26 ) , 15113 – 15118 . 147 . borra , m . t . ; Denu , J . m . Quantitative assays for Characterization of the sir2 family of naD ( + ) - Dependent Deacetylases . Methods Enzymol . 2004 , 376 , 171 – 187 . 148 . howitz , K . t . ; bitterman , K . J . ; Cohen , h . Y . ; lamming , D . W . ; lavu , s . ; Wood , J . g . ; Zipkin , r . e . ; Chung , P . ; Kisielewski , a . ; Zhang , l . l . ; et al . small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan . Nature 2003 , 425 ( 6954 ) , 191 – 196 . 149 . de boer , V . C . ; de goffau , m . C . ; arts , i . C . ; hollman , P . C . ; Keijer , J . sirt1 stimulation by Polyphenols is affected by their stability and metabolism . Mech . Ageing Dev . 2006 , 127 ( 7 ) , 618 – 627 . 150 . borra , m . t . ; smith , b . C . ; Denu , J . m . mechanism of human sirt1 activation by resveratrol . J . Biol . Chem . 2005 , 280 ( 17 ) , 17187 – 17195 . 151 . Kaeberlein , m . ; mcDonagh , t . ; heltweg , b . ; hixon , J . ; Westman , e . a . ; Caldwell , s . D . ; napper , a . ; Curtis , r . ; Distefano , P . s . ; fields , s . ; et al . substrate - specific activation of sirtuins by resveratrol . J . Biol . Chem . 2005 , 280 ( 17 ) , 17038 – 17045 . 152 . Pacholec , m . ; bleasdale , J . e . ; Chrunyk , b . ; Cunningham , D . ; flynn , D . ; griffith , D . a . ; griffor , m . ; loulakis , P . ; Pabst , b . ; Qiu , X . ; et al . srt1720 , srt2183 , srt1460 , and resveratrol are not Direct activators of sirt1 . J . Biol . Chem . 2010 , 285 ( 11 ) , 8340 – 8351 . 153 . huber , J . l . ; mcburney , m . W . ; Distefano , P . s . ; mcDonagh , t . sirt1 - independent mechanisms of the Putative sirtuin enzyme activators srt1720 and srt2183 . Future Med . Chem . 2010 , 2 ( 12 ) , 1751 – 1759 . 154 . geahlen , r . l . ; mclaughlin , J . l . Piceatannol ( 3 , 4 , 3′ , 5′ - tetrahydroxy - trans - stilbene ) is a naturally occurring Protein - tyrosine Kinase inhibitor . Biochem . Biophys . Res . Commun . 1989 , 165 ( 1 ) , 241 – 245 . 155 . Dadi , P . K . ; ahmad , m . ; ahmad , Z . inhibition of atPase activity of Escherichia coli atP synthase by Polyphenols . Int . J . Biol . Macromol . 2009 , 45 ( 1 ) , 72 – 79 . 156 . napper , a . D . ; hixon , J . ; mcDonagh , t . ; Keavey , K . ; Pons , J . f . ; barker , J . ; Yau , W . t . ; amouzegh , P . ; flegg , a . ; hamelin , e . ; et al . Discovery of indoles as Potent and selective inhibitors of the Deacetylase sirt1 . J . Med . Chem . 2005 , 48 ( 25 ) , 8045 – 8054 . 157 . solomon , J . m . ; Pasupuleti , r . ; Xu , l . ; mcDonagh , t . ; Curtis , r . ; Distefano , P . s . ; huber , l . J . inhibition of sirt1 Catalytic activity increases p53 acetylation but Does not alter Cell survival following Dna Damage . Mol . Cell . Biol . 2006 , 26 ( 1 ) , 28 – 38 . 158 . Joubel , a . ; Chalkley , r . J . ; medzihradszky , K . f . ; hondermarck , h . ; burlingame , a . l . identification of new p53 acetylation sites in Cos - 1 Cells . Mol . Cell . Proteomics 2009 , 8 ( 6 ) , 1167 – 1173 . 159 . Vakhrusheva , o . ; smolka , C . ; gajawada , P . ; Kostin , s . ; boettger , t . ; Kubin , t . ; braun , t . ; bober , e . sirt7 increases stress resistance of Cardiomyocytes and Prevents apoptosis and inflammatory Cardiomyopathy in mice . Circ . Res . 2008 , 102 ( 6 ) , 703 – 710 . 160 . heltweg , b . ; gatbonton , t . ; schuler , a . D . ; Posakony , J . ; li , h . ; goehle , s . ; Kollipara , r . ; Depinho , r . a . ; gu , Y . ; simon , J . a . ; et al . antitumor Stünkel and campbell 1168 www . slas . org Journal of biomolecular Screening 16 ( 10 ) ; 2011 activity of a small - molecule inhibitor of human silent information regulator 2 enzymes . Cancer Res . 2006 , 66 ( 8 ) , 4368 – 4377 . 161 . lara , e . ; mai , a . ; Calvanese , V . ; altucci , l . ; lopez - nieva , P . ; martinez - Chantar , m . l . ; Varela - rey , m . ; rotili , D . ; nebbioso , a . ; ropero , s . ; et al . salermide , a sirtuin inhibitor with a strong Cancer - specific Proapoptotic effect . Oncogene 2009 , 28 ( 6 ) , 781 – 791 . 162 . Kalle , a . m . ; mallika , a . ; badiger , J . ; alinakhi ; talukdar , P . ; sachchidanand . inhibition of sirt1 by a small molecule induces apoptosis in breast Cancer Cells . Biochem . Biophys . Res . Commun . 2010 , 401 ( 1 ) , 13 – 19 . 163 . trapp , J . ; meier , r . ; hongwiset , D . ; Kassack , m . u . ; sippl , W . ; Jung , m . structure - activity studies on suramin analogues as inhibitors of naD + - Dependent histone Deacetylases ( sirtuins ) . ChemMedChem 2007 , 2 ( 10 ) , 1419 – 1431 . 164 . lain , s . ; hollick , J . J . ; Campbell , J . ; staples , o . D . ; higgins , m . ; aoubala , m . ; mcCarthy , a . ; appleyard , V . ; murray , K . e . ; baker , l . ; et al . Discovery , in Vivo activity , and mechanism of action of a small - molecule p53 activator . Cancer Cell 2008 , 13 ( 5 ) , 454 – 463 . 165 . huhtiniemi , t . ; suuronen , t . ; lahtela - Kakkonen , m . ; bruijn , t . ; Jääskeläinen , s . ; Poso , a . ; salminen , a . ; leppänen , J . ; Jarho , e . n ( epsilon ) - modified lysine Containing inhibitors for sirt1 and sirt2 . Bioorg . Med . Chem . 2010 , 18 ( 15 ) , 5616 – 5625 . 166 . Kiviranta , P . h . ; suuronen , t . ; Wallen , e . a . ; leppanen , J . ; tervonen , J . ; Kyrylenko , s . ; salminen , a . ; Poso , a . ; Jarho , e . m . n ( epsilon ) - thioacetyl - lysine - Containing tri - , tetra - , and Pentapeptides as sirt1 and sirt2 inhibitors . J . Med . Chem . 2009 , 52 ( 7 ) , 2153 – 2156 . 167 . medda , f . ; russell , r . J . ; higgins , m . ; mcCarthy , a . r . ; Campbell , J . ; slawin , a . m . ; lane , D . P . ; lain , s . ; Westwood , n . J . novel Cambinol analogs as sirtuin inhibitors : synthesis , biological evaluation , and rationalization of activity . J . Med . Chem . 2009 , 52 ( 9 ) , 2673 – 2682 . 168 . sanders , b . D . ; Jackson , b . ; brent , m . ; taylor , a . m . ; Dang , W . ; berger , s . l . ; schreiber , s . l . ; howitz , K . ; marmorstein , r . identification and Characterization of novel sirtuin inhibitor scaffolds . Bioorg . Med . Chem . 2009 , 17 ( 19 ) , 7031 – 7041 . 169 . Zhao , K . ; Chai , X . ; Clements , a . ; marmorstein , r . structure and autoregulation of the Yeast hst2 homolog of sir2 . Nat . Struct . Biol . 2003 , 10 ( 10 ) , 864 – 871 . 170 . Zhao , K . ; harshaw , r . ; Chai , X . ; marmorstein , r . structural basis for nicotinamide Cleavage and aDP - ribose transfer by naD ( + ) - Dependent sir2 histone / Protein Deacetylases . Proc . Natl . Acad . Sci . U . S . A . 2004 , 101 ( 23 ) , 8563 – 8568 . 171 . sanders , b . D . ; Zhao , K . ; slama , J . t . ; marmorstein , r . structural basis for nicotinamide inhibition and base exchange in sir2 enzymes . Mol . Cell . 2007 , 25 ( 3 ) , 463 – 472 . 172 . Zhao , K . ; Chai , X . ; marmorstein , r . structure and substrate binding Properties of cobb , a sir2 homolog Protein Deacetylase from Escherichia coli . J . Mol . Biol . 2004 , 337 ( 3 ) , 731 – 741 . 173 . hoff , K . g . ; avalos , J . l . ; sens , K . ; Wolberger , C . insights into the sirtuin mechanism from ternary Complexes Containing naD + and acetylated Peptide . Structure 2006 , 14 ( 8 ) , 1231 – 1240 . 174 . Cosgrove , m . s . ; bever , K . ; avalos , J . l . ; muhammad , s . ; Zhang , X . ; Wolberger , C . the structural basis of sirtuin substrate affinity . Biochemistry 2006 , 45 ( 24 ) , 7511 – 7521 . 175 . avalos , J . l . ; bever , K . m . ; Wolberger , C . mechanism of sirtuin inhibition by nicotinamide : altering the naD ( + ) Cosubstrate specificity of a sir2 enzyme . Mol . Cell . 2005 , 17 ( 6 ) , 855 – 868 . 176 . min , J . ; landry , J . ; sternglanz , r . ; Xu , r . m . Crystal structure of a sir2 homolog - naD Complex . Cell 2001 , 105 ( 2 ) , 269 – 279 . 177 . Chang , J . h . ; Kim , h . C . ; hwang , K . Y . ; lee , J . W . ; Jackson , s . P . ; bell , s . D . ; Cho , Y . structural basis for the naD - Dependent Deacetylase mechanism of sir2 . J . Biol . Chem . 2002 , 277 ( 37 ) , 34489 – 34498 . 178 . avalos , J . l . ; Celic , i . ; muhammad , s . ; Cosgrove , m . s . ; boeke , J . D . ; Wolberger , C . structure of a sir2 enzyme bound to an acetylated p53 Peptide . Mol . Cell . 2002 , 10 ( 3 ) , 523 – 535 . 179 . lavu , s . ; boss , o . ; elliott , P . J . ; lambert , P . D . sirtuins—novel therapeutic targets to treat age - associated Diseases . Nat . Rev . Drug Discov . 2008 , 7 ( 10 ) , 841 – 853 . 180 . finnin , m . s . ; Donigian , J . r . ; Pavletich , n . P . structure of the histone Deacetylase sirt2 . Nat . Struct . Biol . 2001 , 8 ( 7 ) , 621 – 625 . 181 . Vaquero , a . ; sternglanz , r . ; reinberg , D . naD + - Dependent Deacetylation of h4 lysine 16 by Class iii hDaCs . Oncogene 2007 , 26 ( 37 ) , 5505 – 5520 . 182 . north , b . J . ; marshall , b . l . ; borra , m . t . ; Denu , J . m . ; Verdin , e . the human sir2 ortholog , sirt2 , is an naD + - Dependent tubulin Deacetylase . Mol . Cell . 2003 , 11 ( 2 ) , 437 – 444 . 183 . Jin , l . ; Wei , W . ; Jiang , Y . ; Peng , h . ; Cai , J . ; mao , C . ; Dai , h . ; Choy , W . ; bemis , J . e . ; Jirousek , m . r . ; et al . Crystal structures of human sirt3 Displaying substrate - induced Conformational Changes . J . Biol . Chem . 2009 , 284 ( 36 ) , 24394 – 24405 . 184 . scher , m . b . ; Vaquero , a . ; reinberg , D . sirt3 is a nuclear naD + - Dependent histone Deacetylase that translocates to the mitochondria upon Cellular stress . Genes Dev . 2007 , 21 ( 8 ) , 920 – 928 . 185 . sundaresan , n . r . ; samant , s . a . ; Pillai , V . b . ; rajamohan , s . b . ; gupta , m . P . sirt3 is a stress - responsive Deacetylase in Cardiomyocytes that Protects Cells from stress - mediated Cell Death by Deacetylation of Ku70 . Mol . Cell . Biol . 2008 , 28 ( 20 ) , 6384 – 6401 . 186 . someya , s . ; Yu , W . ; hallows , W . C . ; Xu , J . ; Vann , J . m . ; leeuwenburgh , C . ; tanokura , m . ; Denu , J . m . ; Prolla , t . a . sirt3 mediates reduction of oxidative Damage and Prevention of age - related hearing loss under Caloric restriction . Cell 2010 , 143 ( 5 ) , 802 – 812 . 187 . schlicker , C . ; gertz , m . ; Papatheodorou , P . ; Kachholz , b . ; becker , C . f . ; steegborn , C . substrates and regulation mechanisms for the human mitochondrial sirtuins sirt3 and sirt5 . J . Mol . Biol . 2008 , 382 ( 3 ) , 790 – 801 . 188 . shimazu , t . ; hirschey , m . D . ; hua , l . ; Dittenhafer - reed , K . e . ; schwer , b . ; lombard , D . b . ; li , Y . ; bunkenborg , J . ; alt , f . W . ; Denu , J . m . ; Jacobson , m . P . ; et al . sirt3 Deacetylates mitochondrial 3 - hydroxy - 3 - methylglutaryl Coa synthase 2 and regulates Ketone body Production . Cell Metab . 2010 , 12 ( 6 ) , 654 – 661 . 189 . schwer , b . ; bunkenborg , J . ; Verdin , r . o . ; andersen , J . s . ; Verdin , e . reversible lysine acetylation Controls the activity of the mitochondrial enzyme acetyl - Coa synthetase 2 . Proc . Natl . Acad . Sci . U . S . A . 2006 , 103 ( 27 ) , 10224 – 10229 . 190 . Cimen , h . ; han , m . J . ; Yang , Y . ; tong , Q . ; Koc , h . ; Koc , e . C . regulation of succinate Dehydrogenase activity by sirt3 in mammalian mitochondria . Biochemistry 2010 , 49 ( 2 ) , 304 – 311 . 191 . Chen , Y . ; Zhang , J . ; lin , Y . ; lei , Q . ; guan , K . l . ; Zhao , s . ; Xiong , Y . tumour suppressor sirt3 Deacetylates and activates manganese superoxide Dismutase to scavenge ros . EMBO Rep . 2011 , 12 ( 6 ) , 534 – 541 . 192 . Qiu , X . ; brown , K . ; hirschey , m . D . ; Verdin , e . ; Chen , D . Calorie restriction reduces oxidative stress by sirt3 - mediated soD2 activation . Cell . Metab . 2010 , 12 ( 6 ) , 662 – 667 . 193 . hirschey , m . D . ; shimazu , t . ; goetzman , e . ; Jing , e . ; schwer , b . ; lombard , D . b . ; grueter , C . a . ; harris , C . ; biddinger , s . ; ilkayeva , o . r . ; Sirtuin 1 ( SIrt1 ) Journal of biomolecular Screening 16 ( 10 ) ; 2011 www . slas . org 1169 et al . sirt3 regulates mitochondrial fatty - acid oxidation by reversible enzyme Deacetylation . Nature 2010 , 464 ( 7285 ) , 121 – 125 . 194 . lombard , D . b . ; alt , f . W . ; Cheng , h . l . ; bunkenborg , J . ; streeper , r . s . ; mostoslavsky , r . ; Kim , J . ; Yancopoulos , g . ; Valenzuela , D . ; murphy , a . ; et al . mammalian sir2 homolog sirt3 regulates global mitochondrial lysine acetylation . Mol . Cell . Biol . 2007 , 27 ( 24 ) , 8807 – 8814 . 195 . ahn , b . h . ; Kim , h . s . ; song , s . ; lee , i . h . ; liu , J . ; Vassilopoulos , a . ; Deng , C . X . ; finkel , t . a role for the mitochondrial Deacetylase sirt3 in regulating energy homeostasis . Proc . Natl . Acad . Sci . U . S . A . 2008 , 105 ( 38 ) , 14447 – 14452 . 196 . haigis , m . C . ; mostoslavsky , r . ; haigis , K . m . ; fahie , K . ; Christodoulou , D . C . ; murphy , a . J . ; Valenzuela , D . m . ; Yancopoulos , g . D . ; Karow , m . ; blander , g . ; et al . sirt4 inhibits glutamate Dehydrogenase and opposes the effects of Calorie restriction in Pancreatic beta Cells . Cell 2006 , 126 ( 5 ) , 941 – 954 . 197 . nasrin , n . ; Wu , X . ; fortier , e . ; feng , Y . ; bare , o . C . ; Chen , s . ; ren , X . ; Wu , Z . ; streeper , r . s . ; bordone , l . sirt4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle Cells . J . Biol . Chem . 2010 , 285 ( 42 ) , 31995 – 32002 . 198 . schuetz , a . ; min , J . ; antoshenko , t . ; Wang , C . l . ; allali - hassani , a . ; Dong , a . ; loppnau , P . ; bochkarev , a . ; sternglanz , r . ; Plotnikov , a . n . structural basis of inhibition of the human naD + - Dependent Deacetylase sirt5 by suramin . Structure 2007 , 15 ( 3 ) , 377 – 389 . 199 . nakagawa , t . ; lomb , D . J . ; haigis , m . C . ; guarente , l . sirt5 Deacetylates Carbamoyl Phosphate synthetase 1 and regulates the urea Cycle . Cell 2009 , 137 ( 3 ) , 560 – 570 . 200 . Kawahara , t . l . ; michishita , e . ; adler , a . s . ; Damian , m . ; berber , e . ; lin , m . ; mcCord , r . a . ; ongaigui , K . C . ; boxer , l . D . ; Chang , h . Y . ; et al . sirt6 links histone h3 lysine 9 Deacetylation to nf - kappab - Dependent gene expression and organismal life span . Cell 2009 , 136 ( 1 ) , 62 – 74 . 201 . michishita , e . ; mcCord , r . a . ; berber , e . ; Kioi , m . ; Padilla - nash , h . ; Damian , m . ; Cheung , P . ; Kusumoto , r . ; Kawahara , t . l . ; barrett , J . C . ; et al . sirt6 is a histone h3 lysine 9 Deacetylase that modulates telomeric Chromatin . Nature 2008 , 452 ( 7186 ) , 492 – 496 . 202 . michishita , e . ; mcCord , r . a . ; boxer , l . D . ; barber , m . f . ; hong , t . ; gozani , o . ; Chua , K . f . Cell Cycle – Dependent Deacetylation of telomeric histone h3 lysine K56 by human sirt6 . Cell Cycle 2009 , 8 ( 16 ) , 2664 – 2666 . 203 . mostoslavsky , r . ; Chua , K . f . ; lombard , D . b . ; Pang , W . W . ; fischer , m . r . ; gellon l , liu P , mostoslavsky , g . ; franco , s . ; murphy , m . m . ; et al . genomic instability and aging - like Phenotype in the absence of mammalian sirt6 . Cell 2006 , 124 ( 2 ) , 315 – 329 . 204 . ford , e . ; Voit , r . ; liszt , g . ; magin , C . ; grummt , i . ; guarente , l . mammalian sir2 homolog sirt7 is an activator of rna Polymerase i transcription . Genes Dev . 2006 , 20 ( 9 ) , 1075 – 1080 . 205 . schmidt , m . t . ; smith , b . C . ; Jackson , m . D . ; Denu , J . m . Coenzyme specificity of sir2 Protein Deacetylases : implications for Physiological regulation . J . Biol . Chem . 2004 , 279 ( 38 ) , 40122 – 40129 . 206 . neugebauer , r . C . ; uchiechowska , u . ; meier , r . ; hruby , h . ; Valkov , V . ; Verdin , e . ; sippl , W . ; Jung , m . structure - activity studies on splitomicin Derivatives as sirtuin inhibitors and Computational Prediction of binding mode . J . Med . Chem . 2008 , 51 ( 5 ) , 1203 – 1213 . 207 . rotili , D . ; tarantino , D . ; Carafa , V . ; lara , e . ; meade , s . ; botta , g . ; nebbioso , a . ; schemies , J . ; Jung , m . ; Kazantsev , a . g . ; et al . identification of tri - and tetracyclic Pyrimidinediones as sirtuin inhibitors . Chem MedChem 2010 , 5 ( 5 ) , 674 – 677 . 208 . Posakony , J . ; hirao , m . ; stevens , s . ; simon , J . a . ; bedalov , a . inhibitors of sir2 : evaluation of splitomicin analogues . J . Med . Chem . 2004 , 47 ( 10 ) , 2635 – 2644 . 209 . mai , a . ; massa , s . ; lavu , s . ; Pezzi , r . ; simeoni , s . ; ragno , r . ; mariotti , f . r . ; Chiani , f . ; Camilloni , g . ; sinclair , D . a . Design , synthesis , and biological evaluation of sirtinol analogues as Class iii histone / Protein Deacetylase ( sirtuin ) inhibitors . J . Med . Chem . 2005 , 48 ( 24 ) , 7789 – 7795 . address correspondence to : Robert M . Campbell Eli Lilly & Company Lilly Corporate Center , dc0424 , Indianapolis , IN 46285 E - mail : campbell _ robert _ morris @ lilly . com